Modeling the personalized variations in liver disease due to α1-antitrypsin deficiency using induced pluripotent stem cell-derived hepatocyte-like cells by Tafaleng, Edgar N.
Modeling the personalized variations in liver disease due to α1-antitrypsin deficiency 
using induced pluripotent stem cell-derived hepatocyte-like cells 
by 
Edgar N. Tafaleng 
BS Molecular Biology and Biotechnology, University of the Philippines - Diliman, 2004 
Submitted to the Graduate Faculty of 
School of Medicine in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy in Cellular and Molecular Pathology 
University of Pittsburgh 
2015 
ii 
UNIVERSITY OF PITTSBURGH 
SCHOOL OF MEDICINE 
This dissertation was presented 
by 
Edgar N. Tafaleng 
It was defended on 
February 12, 2015 
and approved by 
Committee Chair: Donna Beer Stolz, PhD, Associate Professor, Department of Cell Biology 
Andrew W. Duncan, PhD, Assistant Professor, Department of Pathology 
David H. Perlmutter, MD, Vira I. Heinz Professor, Department of Pediatrics 
Steven D. Shapiro, MD, Professor, Department of Medicine 
Dissertation Advisor: Ira J. Fox, MD, Professor, Department of Surgery 
iii 
Copyright © by Edgar N. Tafaleng 
2015 
iv 
In the classical form of α1-antitrypsin deficiency (ATD), aberrant intracellular accumulation of 
misfolded mutant α1-antitrypsin Z (ATZ) in hepatocytes causes hepatic damage by a gain-of-
function, “proteotoxic” mechanism. Whereas some ATD patients develop severe liver disease 
that necessitates liver transplantation, others with the same genetic defect completely escape this 
clinical phenotype. We investigated whether induced pluripotent stem cells (iPSCs) from ATD 
individuals with or without severe liver disease could model these personalized variations in 
hepatic disease phenotypes. Patient-specific iPSCs were generated from ATD patients and a 
control, and differentiated into hepatocyte-like cells (iHeps) having many characteristics of 
hepatocytes. Pulse-chase and endoglycosidase H analysis demonstrate that the iHeps recapitulate 
the abnormal accumulation and processing of the ATZ molecule, compared to the wild-type AT 
molecule. Measurements of the fate of intracellular ATZ show a marked delay in the rate of ATZ 
degradation in iHeps from severe liver disease patients, compared to those from no liver disease 
patients. Transmission electron microscopy showed dilated rough endoplasmic reticulum in 
iHeps from all individuals with ATD, not in controls, but globular inclusions that are partially 
covered with ribosomes were observed only in iHeps from individuals with severe liver disease. 
These results provide definitive validation that iHeps model the individual disease phenotypes of 
ATD patients with more rapid degradation of misfolded ATZ and lack of globular inclusions in 
cells from patients who have escaped liver disease. The results support the concept that 
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v 
“proteostasis” mechanisms, such as intracellular degradation pathways, play a role in observed 
variations in clinical phenotype and show that iPSCs can potentially be used to facilitate 
predictions of disease susceptibility for more precise and timely application of therapeutic 
strategies. 
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PREFACE 
Chapters 2, 3, and 4 of this dissertation contain data from a peer-reviewed published manuscript 
on which I am first author: 
Tafaleng, E.N., Chakraborty, S., Han, B., Hale, P., Wu, W., Soto-Gutierrez, A., Feghali-
Bostwick. C.A., Wilson, A.A., Kotton, D.N., Nagaya, M., Strom, S.C., Roy-Chowdhury, J., 
Stolz, D.B., Perlmutter, D.H., Fox, I.J. Induced pluripotent stem cells model personalized 
variations in liver disease due to α1-antitrypsin deficiency. Hepatology (Baltimore, Md.) 62, 
147-157 (2015).
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1.0  INTRODUCTION 
1.1 ALPHA-1 ANTITRYPSIN 
Alpha-1 antitrypsin (AT) is a secreted glycoprotein consisting of 394 amino acids and 3 
asparagine-linked carbohydrate chains1-3. AT is one of the most abundant glycoproteins in the 
serum, with circulating levels of about 100-300 mg/dl4. It is a liver-derived acute phase protein 
whose plasma concentration increases up to four-fold in response to inflammation and/or injury5, 
6. AT is a serine protease inhibitor (SERPIN) that can inhibit a wide variety of proteases in vitro 
including trypsin, chymotrypsin, cathepsin G, plasmin, thrombin, tissue kallikrein, coagulation 
factor Xa, and plasminogen7-9. However, its main biological role is to inhibit neutrophil elastase, 
a potent protease that can cleave extracellular matrix proteins, coagulation and complement 
proteins and E. coli cell wall components3, 8, 10, 11. Neutrophil elastase is released in response to 
infection or irritants to degrade bacteria and damaged cells but once the insult is resolved, AT is 
mobilized to neutralize neutrophil elastase activity and prevent damage to healthy lung tissues12-
14. 
AT is encoded by the serine protease inhibitor clade A 1 gene (SERPINA1), previously 
designated as the protease inhibitor 1 gene (PI1)15, 16. The 13,947-base gene is located on 
chromosome 14q32.1 and is comprised of 3 non-coding (IA, IB and IC) and four coding exons (II, 
III, IV and V). Carbohydrate attachment occurs on two asparagine residues encoded by exon II 
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and one encoded by exon III while the active site is encoded by exon V17-19. The gene is 
predominantly expressed in hepatocytes and, to a lesser extent, in extrahepatic cells including 
blood monocytes, tissue macrophages, intestinal epithelial cells, respiratory epithelial cells, renal 
tubular epithelial cells, non-parietal cells of the gastric mucosa, and pancreatic islet cells18, 20-22. 
The regulation of basal and induced AT expression is cell-type dependent18, 22-26 and in 
hepatocytes is regulated by three cis-acting elements 5’ of the gene and is predominantly driven 
by the synergistic effects of the hepatocyte nuclear factors HNF1A and HNF4 and modulated by 
IL-6 during the acute phase reaction17, 23, 27-31. 
1.2 CLASSICAL ALPHA-1 ANTITRYPSIN DEFICIENCY 
Studies have reported at least 75 variant alleles in the SERPINA1 gene8, 19. However, the 
overwhelming majority of patients with liver disease are affected by the classical form of alpha-1 
antitrypsin deficiency (ATD) resulting from the protease inhibitor type Z mutation (PiZZ)8, 16, 19. 
This mutation is caused by a homozygous single G11940A nucleotide point mutation in the 
coding region of the SERPINA1 gene32-34. The mutation results in a Glu342Lys amino acid 
substitution that generates an abnormally folded mutant AT protein (ATZ). The ATZ protein has 
an increased tendency to polymerize and form aggregates35. The ATZ mutant protein also has an 
impaired ability to traverse the secretory pathway with only 10-15% of newly synthesized 
proteins released from hepatocytes. Because serum AT levels are only 10% of normal (13-36.4 
mg/dl), there is an apparent “deficiency” in the circulating protease inhibitor activity. The small 
amount of ATZ mutant protein that is released into circulation is functionally active in inhibiting 
neutrophil elastase but has a reduced capacity compared to wild type AT 36-40. 
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ATD is an inborn error of metabolism that was first described in 1963 by Laurell and 
Eriksson4, 41. It is an autosomal genetic condition characterized by low levels of AT in the serum 
and lung1, 8, 19, 41-44. The prevalence of ATD varies in different populations but the disorder 
affects approximately 1 in every 2000-3000 live births in most populations45-49. Although ATD 
was originally discovered as a cause of pulmonary emphysema4, 41, 50, it is now known that ATD 
can also lead to hepatic failure as well as hepatocellular carcinoma15, 51. 
The pathogenesis of emphysema or chronic obstructive pulmonary disease (COPD) 
mediated by ATD is not fully understood although three mechanisms have been proposed. 
Earlier studies have suggested that lung disease is due to a loss-of-function mechanism resulting 
from the deficiency in the circulating protease inhibitor activity. The inadequate serum levels of 
AT leads to diminished ability to inhibit neutrophil elastase from degrading the connective tissue 
components of the extracellular matrix in the lung52-56. Other studies have suggested that lung 
disease is a result of the decreased ability of ATZ to inhibit neutrophil elastase leading to 
uninhibited neutrophil elastase activity40, 57. More recently, however, several groups have 
proposed that lung disease occurs because the pro-inflammatory effects of ATZ polymers 
exacerbate tissue damage that occurs in the lungs. This hypothesis is based on studies reporting 
that ATZ polymers are chemotactic to neutrophils in vivo58, 59, co-localize with neutrophils in the 
alveoli of ATD patients, and can induce inflammation in cell and mouse models of the disease60. 
It is possible that all three of these mechanisms, in addition to environmental factors such as 
cigarette smoke, act together to bring about lung disease in ATD patients.  
The mechanism of ATD-mediated carcinogenesis is, likewise, not fully understood. 
Studies of liver specimens from ATD patients and ATD mouse models revealed distinct 
subpopulations of globule-containing and globule-devoid hepatocytes. Analysis of these two 
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subpopulations revealed that there is increased authophagy, activated NFkB, impaired 
proliferation, and increased levels of apoptosis in globule-containing cells suggesting that these 
cells are injured61, 62. Analyses of cell proliferation using BrdU incorporation have also shown 
that globule-devoid hepatocytes have a proliferative advantage over globule-containing 
hepatocytes63. These studies provide evidence for the hypothesis that carcinogenesis occurs 
because injured globule-containing cells release proliferative signals that chronically stimulate 
globule-devoid cells to divide. 
1.3 ALPHA-1 ANTITRYPSIN DEFICIENCY-MEDIATED LIVER DISEASE 
ATD is the most common genetic cause for liver disease in children. Although other mutations in 
the protease inhibitor gene can result in liver disease, the majority of ATD-mediated liver disease 
is caused by the classical mutation of ATD8, 16, 19. Hepatic failure due to ATD is a result of a gain 
of toxic function mechanism. Several studies have shown that the polymerization of ATZ within 
hepatocytes leads to hepatocyte damage and cirrhosis. However, the molecular mechanisms that 
occur between the onset of ATZ accumulation and hepatotoxicity have not been fully 
determined. Studies using animal and cell models of ATD and liver biopsies from ATD patients 
have implicated mitochondrial injury, mitochondrial autophagy, and caspase activation in the 
pathogenesis of ATD-mediated hepatic failure61-74. However, the pathway/s that link ATZ 
accumulation to mitochondrial injury, mitochondrial autophagy, and caspase activation is still 
unknown. In addition, there is a wide variability in incidence, severity and age of onset of ATD-
mediated liver disease15. While some affected PiZZ individuals develop life-threatening liver 
 5 
disease, a considerable number never develop clinical symptoms and in some cases the liver 
disease is first recognizable at 50-65 years of age.  
While ATD-related liver disease presents with similar clinical manifestations as other 
forms of liver diseases, it can be distinguished by low serum levels of AT protein, about 10-15% 
of normal levels75. Clinical diagnosis for ATD begins with the determination of AT serum levels 
by rocket immunoelectrophoresis, radial immunodiffusion, or nephelometry. Diagnosis can be 
confirmed by isoelectric focusing (IEF) of serum AT and more recently by genotyping through 
PCR or gene sequencing76. Histological analyses of liver biopsies from affected patients also 
show the presence of PAS+/diastase resistant globules in the ER of some but not all hepatocytes 
of affected patients. There is also compelling evidence of mitochondrial injury and heightened 
autophagic activity in liver biopsies from patients75. 
1.4 MODELS FOR ATD-MEDIATED LIVER DISEASE 
The PiZ mouse is a well-characterized in vivo model of ATD that expresses the human PiZ gene 
variant77. The model is able to recapitulate many of the characteristics of the human condition 
including the accumulation of ATZ mutant proteins within the rER of hepatocytes, the presence 
of PAS+/diastase resistant intrahepatocytic globules in liver tissues, and the development of liver 
necrosis/inflammation and hepatocellular carcinoma. The fact that this model recapitulates the 
abnormalities associated with ATD even though the endogenous mouse AT orthologs are 
expressed in the mouse supports the idea that the ATD is due to a gain-of-function rather than a 
loss-of-function mechanism. 
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Studies using the PiZ mouse have improved our understanding of the pathobiology of 
ATD. ATZ accumulation in the PiZ mouse hepatocytes results in caspase 3 and caspase 9 
activation indicating that ATZ accumulation leads to ATD-associated hepatotoxicity63, 64. ATZ 
accumulation in the PiZ mouse liver also leads to the constitutive activation of the autophagic 
response that could not be further activated in the presence of additional physiological stress 
such as fasting65. This autophagic response has been subsequently shown to affect the 
mitochondria leading to mitochondrial autophagy and mitochondrial injury that can be 
ameliorated by the treatment with cyclosporine A, an inhibitor of mitochondrial permeability 
transition64. Further activation of autophagy by carbamazepine (CBZ) treatment lowered the 
levels of ATZ protein, decreased the number of globule-containing hepatocytes and reduced 
hepatic fibrosis66 demonstrating the importance of autophagy as a cellular mechanism for 
protection against ATZ accumulation. Finally, the accumulation of ATZ in the liver of male PiZ 
mice also leads to the hepatocyte hyperproliferation due to testosterone-induced ATZ mRNA 
upregulation. In addition, hepatocytes devoid of ATZ globules were shown to have a relative 
proliferative advantage over globule-containing cells63. All in all, these studies using the PiZ 
mouse model have revealed how ATZ accumulation might lead to liver injury and hepatocellular 
carcinoma and how hepatocytes respond to ATZ mutant protein accumulation. 
The Z mouse is another transgenic mouse model for AT in which liver-specific 
expression of ATZ is turned off by doxycycline treatment of animals61. Accumulation of ATZ in 
the Z mouse activates signaling pathways including caspase 12, and NFkB but does not result in 
the induction of BiP or in the cleavage of XBP1 mRNA. In addition, microarray analysis of the Z 
mouse liver did not show changes in expression of any of the known target genes of the UPR. 
These results indicate that the accumulation of mutant ATZ activates specific signaling pathways 
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that are different from those activated by other nonpolymerogenic AT mutant variants61. By 
crossing the Z mouse with the GFP-LC3 mouse, it was also determined that the expression of 
ATZ in liver is sufficient to induce autophagy, thus definitively confirming the results observed 
in the PiZ mouse62. 
More recently, a Caenorhabditis elegans model for ATD has been developed by 
expressing the GFP-tagged ATZ gene under the intestinal-specific promoter of nhx-267. In this 
model, ATZ forms aggregates in the endoplasmic reticulum of intestinal cells. Studies employing 
genome-wide RNAi screens and genetic crosses using this model system have identified genetic 
modifiers affecting the accumulation of the alpha-1 antitrypsin Z mutant (ATZ)69, 70. Moreover, 
results of genome-wide RNAi screens, genetic crosses, and pharmacological screens in this 
model for ATD identified autophagy and ER-associated degradation (ERAD) pathways as 
critical for the degradation of intracellular ATZ67-70. 
Various cell lines and patient derived-fibroblasts engineered to express the ATZ mutant 
protein have also been used to study ATD. Similar to results in mouse models of ATD, ATZ 
accumulation in human fibroblasts also resulted in the increased autophagic response71. In 
addition, ATZ protein accumulation in human and mouse cell lines led to the activation of 
caspase 4, caspase 12, NFkB, and BAP31 but not the members of unfolded protein response 
pathway61. Furthermore, studies show that proteasomal degradation is crucial for the disposal of 
accumulated ATZ proteins in the ER of ATZ-expressing cell lines72 and ATZ-expressing 
fibroblasts73. More recently, a study using Atg5-deficient mouse embryonic fibroblasts 
expressing ATZ, also showed that the absence of autophagy results in a reduced rate of ATZ 
degradation, and increased formation of cytoplasmic ATZ inclusions62. Using ATZ-expressing 
dermal fibroblasts from PiZZ patients with liver disease (susceptible hosts) and those without 
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liver disease (protected hosts), a study demonstrated that there was a lag in the degradation of 
ATZ mutant proteins in susceptible compared to protected hosts74. This suggests that genetic 
factors that influence the degradation of ATZ mutant proteins may confer susceptibility to liver 
disease. These studies reveal the cellular processes activated by ATZ accumulation and the 
factors that could predispose ATD patients to liver disease. 
1.5 INDUCED PLURIPOTENT STEM CELLS 
Human embryonic stem cells (hEScs) hold great promise for biomedical and clinical research 
because they have the ability to self-renew indefinitely and the capacity to differentiate into all 
somatic cell types in the body78, 79. hEScs can thus potentially be an unlimited source of cells for 
disease modeling, drug discovery studies and the treatment of diseases and injuries78, 79. 
However, the use of hEScs for research has been impeded because of ethical concerns related to 
the destruction of human embryos80. Thus, considerable effort has been expended into 
developing or discovering cells that have equivalent capabilities as hEScs but that do not involve 
the destruction of human embryos. 
Landmark studies in 2007 demonstrated the conversion of somatic cells into cells that 
closely resemble hEScs81, 82. These cells, termed induced pluripotent stem cells (iPScs), are able 
to self-renew indefinitely and can differentiate into all somatic cell types81, 82. Since iPScs are 
generated without destroying human embryos, it circumvents the ethical concerns that have 
limited the use of hEScs. iPScs are cells that have been reprogrammed to a pluripotent state by 
forced expression of exogenous genes and factors that are required for maintaining the defining 
characteristics of embryonic stem cells81-83. iPScs were first generated from mouse cells in 2006 
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by Takahashi and Yamanaka when they successfully reprogrammed mouse fibroblasts through 
retroviral transduction with four transcription factors, octamer-binding transcription factor 3/4 
(Oct3/4), SRY-box 2 (Sox2), c-Myc, and Kruppel-like factor 4 (Klf4)83. Like mouse embryonic 
stem cells (mEScs), the mouse iPScs expressed alkaline phosphatase (AP), the mESc-specific 
surface marker stage-specific embryonic antigen 1 (SSEA1), and Nanog. They were also able to 
differentiate into all three germ layers in vitro, and form teratomas when subcutaneously injected 
into immunodeficient mice. 
Shortly after, in 2007, two groups demonstrated the reprogramming of human embryonic, 
neonatal and adult fibroblasts into iPScs using retroviral81- or lentiviral82- mediated approaches. 
In these studies, human iPScs were isolated based on the distinct human hESc colony 
morphology. Like hEScs, human iPScs were positive for alkaline phosphatase (AP), OCT3/4, 
NANOG, and the cell surface markers stage-specific embryonic antigen 3 (SSEA3), stage-
specific embryonic antigen 4 (SSEA 4), tumor-related antigen 160 (TRA160) and tumor-related 
antigen 181 (TRA181). The human iPScs also have the ability to differentiate into all three germ 
layers in vitro and generate mature teratomas when injected into immunodeficient mice. Using 
genome-wide microarray analysis, it was determined that the expression pattern of human iPScs 
is more similar to hEScs than to fibroblasts and that a majority of hESc-specific genes are 
reactivated following reprogramming. One group achieved successful reprogramming using the 
human orthologs of the same four factors that were used for mouse fibroblasts83 with ~0.02% 
efficiency 30 days post transduction81. The other group used a different combination of four 
factors that replaced c-MYC and KLF4 with NANOG and a RNA binding protein LIN28 with 
0.01-0.05% efficiency 20 days post transduction82. The identification of novel combinations of 
pluripotency factors indicates that reprogramming could be achieved through several different 
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transcription factor networks although OCT3/4 and SOX2 appear to be essential for this 
process81, 82, 84. However, whether the iPScs generated through distinct combinations of factors 
are identical remains to be determined. 
1.6 GENERATION OF INDUCED PLURIPOTENT STEM CELLS 
Like hEScs, iPScs can self-renew indefinitely and are able to differentiate into cell lineages from 
all three germ layers81, 82. Unlike hEScs, the use of iPScs is not ethically controversial. In 
addition, iPScs have the unique advantage of being donor-specific and therefore, have generated 
interest in the field of regenerative medicine and personalized drug testing. There are however, 
some caveats with the use of iPScs. Initial methods for the generation of iPScs involved the 
introduction of potential oncogenes delivered using either retrovirus or lentivirus81, 82. This 
method has been particularly problematic because there are possible indirect negative effects 
because the insertion of exogenous genes in the host cell genome is random. This has been 
shown to occur in a viral-mediated gene therapy trial where transgene insertion could elevate the 
expression of nearby endogenous oncogenic factors that could lead to leukemia85. Moreover, 
because viral gene integration is permanent and irreversible81, 82 there is always a risk for 
tumorigenesis due to possible reactivation and overexpression of oncogenic transgenes after 
silencing83, 86. In addition, the low reprogramming efficiency (0.01-0.05%) associated with initial 
reprogramming methods is a major hurdle for the generation of iPScs. In order to circumvent 
these problems, several groups aimed to develop novel reprogramming methods that involve 
either transient expression of pluripotency factors or using chemical modulators to efficiently 
generate clinically useful iPScs. 
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To avoid the potential problems that are associated with first generation reprogramming 
techniques, one group developed a lentiviral vector carrying a single stem cell cassette 
(STEMCCA) that contains the four Yamanaka factors (OCT3/4, SOX2, KLF4, and c-MYC)87. 
The vector was engineered to carry all the reprogramming factors and contain self-cleaving 
peptide signals in between each of the reprogramming factors as well as loxP sites at either end 
of the transgene. The technique has several advantages over earlier reprogramming techniques. 
Unlike retroviruses, lentiviruses can infect both non-proliferating and proliferating cells and has 
thus become the preferred vehicle for delivering reprogramming factors in somatic cells. In 
addition, the reprogramming efficiency achieved using a single cassette was superior compared 
to using four or more vectors. Finally, concern about lentiviral transgene incorporation into the 
host cell genome was addressed by the addition of loxP sites. After successful reprogramming of 
host cells, the integrated viral sequence could be excised by the overexpression of Cre-
recombinase using either plasmids or adenoviruses. After Cre-mediated excision of transgene 
sequences it was shown that the iPScs retained their pluripotency and their ability to 
differentiate. This method has now been widely used to generate iPScs with reprogramming 
efficiencies of 0.1–1.5%. However, this technique still leaves undesirable alterations to the host 
genome because loxP sites are not removed by Cre-mediated excision. 
Episomal plasmids have also been used for the transient expression of reprogramming 
factors allowing for the generation of integration-free iPScs. For this method, plasmids 
containing the OriP/EBNA-1 (Epstein-Barr nuclear antigen-1) backbone are used because they 
can stably express reprogramming factors for a longer period of time allowing for 
reprogramming to occur. In one study, nucleofection of human foreskin fibroblasts with three 
oriP/EBNA-1 plasmids containing the reprogramming factors OCT3/4, SOX2, NANOG, KLF4, c-
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MYC, and LIN28 and SV40 large T antigen led to 0.0003-0.0006% reprogramming efficiency 
after 20 days88. However, it is likely that the episomal vector integrated into the host genome as 
only one-third of the subclones from two of the original iPSc lines lost the episomal plasmid. 
The same group subsequently reported that the efficiency of episomal plasmid-mediated 
reprogramming is cell type dependent by showing that blood mononuclear cells (BM) can be 
reprogrammed more efficiently than fibroblasts (0.0352-0.2095% vs 0.0003-0.0356%). 
Moreover, the addition of the small molecule thiazovivin led to an increase in reprogramming 
efficiency of cord blood cells by more than ten-fold89. In contrast to the initial paper, 
reprogramming occurred within 12 days and all the iPScs lost the plasmid by passage 15. 
Another study described plasmid-mediated reprogramming using a different combination of 
reprogramming factors. In the study, the electroporation of human dermal fibroblasts and dental 
pulp cells with three oriP/EBNA-1 expression plasmids encoding OCT3/4 and P53 shRNA, 
SOX2 and KLF4, l-MYC and LIN28, resulted in reprogramming a efficiency of 0.03%90. In this 
study, five out of the seven iPSc clones tested negative for the EBNA-1 DNA after 11-20 
passages. This suggests that the episomal vectors were spontaneously lost in majority of the 
iPScs. Overall, episomal plasmid-mediated reprogramming is an effective strategy for generating 
footprint-free iPScs although downstream analyses of iPScs have to be performed to identify the 
small number of iPS clones with random plasmid integration. 
The use of mRNA as a method for obtaining footprint-free iPScs has also been 
reported91. The transfection of human fibroblasts with modified mRNA expressing the 
Yamanaka factors resulted in 1.4% reprogramming efficiency within 20 days. Further 
optimization studies determined that the inclusion of LIN28 to the Yamanaka factors, incubation 
of the cells at 5% CO2, and the addition of valproic acid to the medium increased the efficiency 
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to 4.4%91. However, this method is expensive and labor intensive because cells have to be 
transfected with modified mRNA for 17 days. Moreover, mRNA-based reprogramming kits have 
so far only been validated in fibroblasts. 
The use of reprograming factors in the form of proteins can be an ideal approach to 
generate integration-free iPScs. However, the production of large quantities of bioactive proteins 
able to pass through the plasma membrane has been technically difficult. One study was able to 
produce reprogramming proteins (OCT3/4, SOX2, KLF4, and c-MYC) each fused with a cell 
penetrating peptide (CPP) composed of nine arginine residues using an HEK 293 system92. 
Direct treatment of human newborn fibroblasts with supernatant containing the CPP-anchored 
reprogramming proteins for six cycles resulted in stable iPScs from human newborn fibroblasts 
within 8 weeks at an efficiency of 0.001%. Although successful at generating iPScs, this 
reprogramming strategy is slow and inefficient and has not been tested on non-fibroblast cells. 
This approach therefore needs to be optimized in order to become a viable reprogramming 
method. 
1.7 DISEASE-SPECIFIC INDUCED PLURIPOTENT STEM CELLS 
Because of significant research advances in recent years, the pathophysiological mechanisms 
underlying various chronic diseases and disorders have been elucidated and therapies for their 
treatment have subsequently been developed. However, for some diseases and disorders the 
underlying mechanisms remain elusive because of the lack of disease models reflecting human 
pathogenesis. The lack of appropriate human models for these diseases and disorders has 
hampered the development of novel treatments and therapies. Cell line and animal disease 
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models have been developed for some of these disorders but there has been much debate as to 
whether these can accurately reflect the mechanisms that actually occur in the human setting 
because of cell line-specific and species-specific differences. 
The advent of iPSc technology and the development of techniques for in vitro 
differentiation of pluripotent stem cells toward several somatic cells have paved a way for a new 
source of human cells for disease modeling. Because iPScs are donor-specific, reprogramming of 
cells from an individual affected by a genetic disease generates iPScs that carry patient-specific 
genetic information. These disease-specific iPScs offer a unique opportunity to produce 
unlimited numbers of cell types affected by each patient’s disease. The differentiated cells could 
then be used for modeling diseases and developing novel drugs or therapies. Neurological 
disorders, cardiac diseases and metabolic disorders have now been extensively modeled using 
iPSc technology (Table 1). 
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Table 1. Diseases modeled using induced pluripotent stem cell technology 
Disorder References 
Amyotrophic lateral sclerosis 93 
Adenosine deaminase deficiency-related SCID 94 
Shwachman-Bodian-Diamond syndrome 94 
Gaucher disease type III 94 
Duchenne muscular dystrophy 94 
Becker muscular dystrophy 94 
Parkinson disease 94 
Huntington disease 94 
Juvenile-onset, type 1 diabetes mellitus 94 
Down syndrome (trisomy 21) 94 
The carrier state of Lesch-Nyhan syndrome 94 
Spinal muscular atrophy 95 
Idiopathic Parkinson’s disease 96 
ATD 97 
Glycogen storage disease type 1a 97 
Crigler-Najjar syndrome 97 
Familial hypercholesterolemia 97, 98 
Hereditary tyrosinemia type 1 97 
Wilson’s disease 99 
Familial transthyretin amyloidosis 100 
Arrhythmogenic right ventricular cardiomyopathy 101 
Long QT syndrome type 3 102 
Aside from modeling various pathologies, iPSc technology could also be used to 
determine the link between mutations and their corresponding phenotype. The use of isogenic 
iPSc lines, which carry the same genetic information except for the gene of interest, allowed 
researchers to adequately determine changes in phenotype due to changes in a single gene. 
Genomic editing methods using Zinc Finger Nucleases (ZFN)103 and piggyBac technology104, 105, 
Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/CRISPR-associated 
nuclease 9 (Cas9) system106 or Transcription Activator-Like Effector Nucleases (TALENs)107 
have already been used to generate isogenic iPScs/hEScs. Indeed, recent studies have shown that 
the correction of disease-causing single mutations in iPScs results in the abrogation of disease 
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phenotypes indicating that these mutations are necessary for generating disease phenotypes108-112. 
One study also demonstrated that the targeted knock-in of the G2019S mutation in the Leucine-
rich repeat kinase 2 (LRRK2) gene is sufficient to impart a Parkinson’s disease phenotype on 
normal human embryonic stem cells (hEScs)113. 
While disease-specific iPSc have provided an exciting tool to recapitulate known defects 
and uncover new mechanisms underlying human disease, there are still some limitations with 
using this technology for modeling and drug discovery. There is a need to ensure equivalence in 
the degree of maturation between the cells in order to achieve realistic comparisons between 
pathologic adult cells and disease-specific iPSc-derived cells. One study has shown that the gene 
expression profile of hESc-derived neurons were more similar to fetal neurons rather than adult 
ones114. Another study showed that the expression profile of cardiac-specific myosin heavy and 
light chains, cardiac troponin, ion channels, and actin related genes in iPSc-derived 
cardiomyocytes more closely resembled fetal cardiomyocytes than adult cardiomyocytes115. 
Finally, several groups have shown the persistent expression of the fetal hepatocyte marker 
alpha-fetoprotein by iPSc-derived hepatocytes which implies an immature phenotype97, 116, 117. 
Modeling genetic diseases using iPSc technology is limited by the degree of maturation of 
differentiated cells. Modeling late-onset diseases would therefore be difficult unless new 
techniques are developed to improve the maturation of iPSc-derived cells. 
1.8 DIFFERENTIATION OF IPSCS INTO HEPATOCYTES 
Human hepatocytes are important for use in both therapeutic and experimental applications. The 
clinical transplantation of hepatocytes for the correction of certain metabolic liver disorders has 
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been an appealing prospect because the liver is amenable to the introduction of exogenous 
hepatocytes118-123. There has also been a great deal of interest with the use of hepatocytes for 
disease modeling and drug discovery because hepatocytes are sites of drug metabolism and 
detoxification, are affected by several metabolic diseases, and are targeted by many pathogens 
that cause severe liver disease124. However, the supply of primary human hepatocytes suitable 
for these applications cannot currently meet the demand, due to limited donor availability and 
inconsistent quality. Hepatocytes rapidly dedifferentiate and lose most of their liver specific gene 
expression and metabolic activity when grown in vitro125, 126.  In addition, cryopreservation of 
primary hepatocytes leads to reduced viability and metabolic function after thawing87, 127-136. 
These constraints have therefore prompted a search for alternative sources of hepatocytes for 
both clinical and research purposes. 
Numerous studies have described the differentiation of hEScs into cells that display 
several hepatocyte characteristics137-144. Although the protocols differ in the initial stage of 
differentiation, with some starting with a monolayer of cells while others with a three-
dimensional cell aggregate called embryoid body (EB), all the of them aim to recapitulate the 
developmental cues that occur during hepatogenesis, a process that involves a well-coordinated 
interaction between the definitive endoderm (DE), cardiac mesoderm and septum transversum 
mesenchyme. The methods generally follow a series of steps that involve definitive endoderm 
induction, hepatic induction and hepatic maturation142-148. This involves treating the cells with 
growth factors that are involved in each of the steps during development in vivo, such as 
mimicking Nodal expression by Activin A to induce definitive endoderm, treating with various 
fibroblast growth factors (FGF) and bone morphogenetic proteins (BMPs) to recapitulate 
secretion by the cardiac mesoderm and septum transversum mesenchyme, and hepatocyte growth 
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factor (HGF) to induce proliferation and maturation of hepatic progenitors149-152. One study 
employed a 3-step protocol involving definitive endoderm induction, hepatic induction and 
hepatocyte maturation to generate hepatocyte-like cells that upon subsequent selection for 
asialoglycoprotein receptor 1 (ASGPR1) positive cells led to a population of hepatocytes similar 
to primary human hepatocytes in culture142. These cells expressed hepatic genes and did not 
express genes associated with other developmental lineages. The cells secrete ALB, AT, urea, 
and functional coagulation factor VII (F7) and in addition, the cells exhibit inducible and 
functional cytochrome p450 (CYP) activity. More importantly, the cells are able to engraft and 
repopulate in rodent livers. 
The successful production of hESc-derived hepatocytes provided the foundation for 
producing patient-specific hepatocytes from iPScs. The generation of iPSc-derived hepatocytes 
from patients is particularly exciting because it would provide disease-specific hepatocytes for 
disease modeling and drug testing. Additionally, it would provide autologous hepatocytes that 
can be genetically corrected and transplanted back into the patient. Several studies have reported 
the differentiation of iPScs into hepatocyte-like cells. The first study reported the differentiation 
of iPScs into hepatocyte-like cells following a 4-step protocol involving DE induction, hepatic 
specification, hepatoblast expansion, and hepatic maturation117. The expression of hepatic 
markers and liver-related functions of the iPSc-derived hepatic cells were similar to that of the 
hepatocytes except for alpha-fetoprotein (AFP) and cytokeratin 19 (CK19). The differentiated 
cells also exhibited liver cell functions including ALB secretion, glycogen synthesis, urea 
production and inducible CYP activity although the levels are significantly less than human 
hepatocyte activity. Another study described a 4-step approach involving DE induction at 
ambient O2 levels, hepatic specification at 4% O2 levels, hepatic induction at 4% O2 levels, and 
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hepatic maturation at ambient O2 levels116. The differentiated cells possessed a hepatocyte 
mRNA fingerprint that is similar to hESc-derived hepatocyte-like cells. The differentiated cells 
also performed several hepatic functions including the accumulation of glycogen and lipids, 
metabolism of indocyanine green, uptake of low-density lipoprotein, and synthesis of urea 
although the functionality of the cells were not compared to primary human hepatocytes. More 
importantly, the iPSc-derived hepatocytes exhibited short-term engraftment when transplanted in 
mouse liver. Subsequently, another group reported successful differentiation of liver disease-
specific iPScs into hepatocyte-like cells using a 3-step method97. Electron microscopy of 
differentiated cells showed the presence of glycogen deposits and apical microvilli as well as 
prominent nuclei, Golgi bodies and endoplasmic reticulum. The resulting cells are also able to 
store glycogen and LDL, secrete ALB, and metabolize drugs via the CYP pathway although the 
functionality of the cells were not compared to primary human hepatocytes. These studies 
provide proof that iPScs can be efficiently differentiated into hepatocyte-like cells in vitro. 
1.9 DISEASE MODELING USING IPSC-DERIVED HEPATOCYTE-LIKE CELLS 
The ability to conduct mechanistic studies on live human hepatocytes would facilitate the 
discovery of mechanisms underlying liver diseases and the development of novel treatments or 
therapies. However, liver tissues are not readily available especially those that are from patients 
affected by relatively rare liver diseases. In addition, although well-developed protocols are 
available for hepatocyte isolation from liver tissues, the isolation of hepatocytes from cirrhotic 
liver tissues is challenging. Moreover, hepatocytes isolated from liver tissues can only provide 
information about the latter stages of the disease. Various cell lines and inbred animals have 
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therefore been utilized as models to study liver diseases. Although considerable insights into 
human liver disease pathology have been revealed using these model systems, these systems lack 
the significant genetic diversity of humans and for some diseases only display an approximate 
resemblance to the human disease. 
The generation of hepatocyte-like cells (iHeps) from disease-specific human iPScs 
provides a unique platform for understanding liver disease biology and identifying and testing 
novel treatments. In the past five years, several studies have reported the use of disease-specific 
iHeps from patients with metabolic liver diseases to model the diseases in vitro. iHeps generated 
from patients with ATD showed the accumulation of AT polymers in ATD iHeps but not in 
control iHeps. The localization of AT polymers in the ER of the cells was also confirmed by 
subcellular fractionation and endoglycosidase H digestion97. iHeps generated from a patient with 
familial hypercholesterolemia (FH) displayed the absence of the low-density lipoprotein receptor 
(LDLR). The FH iHeps also exhibited the known functional abnormality characteristic of LDLR 
deficiency that was evident by an impaired ability to incorporate LDL97. In another study, iHeps 
from a FH patient with mutations in the LDLR gene that leads to homozygous loss of LDLR 
function (but not expression) exhibited inefficient uptake of LDL-cholesterol (LDL-C) and 
increased secretion of lipidated apolipoprotein B-100. More importantly, the study showed that 
upon treatment with the hepatoselective lipid-lowering drug lovastatin, FH iHeps have an 
increased ability for LDL uptake98. iHeps generated from a patient with glycogen storage disease 
type 1a (GSD1a) exhibited elevated accumulation of intracellular lipid and glycogen, as well as 
excessive production of lactic acid97. iHeps from a patient with Wilson’s disease (WD) exhibited 
abnormal cytoplasmic localization of the mutated Cu2+ Transporting ATPase Beta (ATP7B) 
protein and significantly reduced copper-export activity. In addition, the study showed that the 
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functional defect of the WD iHeps could be rescued in vitro by transduction with a lentiviral 
vector that expresses codon optimized-ATP7B or treatment with the chaperone drug curcumin99. 
iHeps have also been used to model familial transthyretin amyloidosis (ATTR), a multisystem 
disorder caused by mutations in the transthyretin (TTR) gene100. In this protein-folding disorder, 
the mutant TTR protein that is produced by hepatocytes aggregates and forms fibrils in the heart 
and peripheral nervous system. In the study, iHeps, cardiomyocytes and neurons were generated 
from ATTR patient-specific iPScs. iPSc-derived cardiomyocytes and neurons displayed 
oxidative stress, increased cell death, and upregulation of ATTR disease-associated genes when 
exposed to mutant TTR produced by the patient-matched iHeps, recapitulating the reported 
observations in both in vivo and  in vitro model systems. Treatment of mutant TTR-exposed 
cardiomyocytes and neurons with small molecule TTR stabilizers ameliorated this pathology in 
vitro. All in all, these studies demonstrate not only the ability of iHeps to recapitulate the 
complex pathophysiology of several metabolic liver diseases in culture, but also their capacity to 
be used as a system for developing novel therapies or therapeutics for liver disease. 
1.10 SPECIFIC AIMS 
Classical alpha-1 antitrypsin deficiency (ATD) is caused by the PIZZ mutation, a homozygous 
single nucleotide G11940A substitution in the protease inhibitor gene (PI) that produces a mutant 
alpha-1 antitrypsin (AT) protein variant called ATZ. Hepatic dysfunction caused by ATD results 
from the toxic effects of ATZ accumulation within the endoplasmic reticulum (ER) of 
hepatocytes, the major site of AT synthesis. While some ATD patients develop severe liver 
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disease that necessitates liver transplantation, others with the same genetic defect completely 
escape this clinical phenotype15. 
The limited number of patient-derived live human hepatocytes from ATD patients 
presents a major obstacle for understanding this observed variability in liver disease phenotype. 
While liver tissue from patients can be used for analyses, these samples can only reveal aspects 
of the disease at its culmination64, 153. Studies using cellular and animal model systems have 
provided invaluable insights into the pathobiology of the disease62, 64, 66, 68, 71, 72, 74, 154-156. 
However, except for patient-derived fibroblasts74, these model systems lack the genetic diversity 
of humans that seems to be at least partly responsible for the observed variation in liver disease 
phenotype74. Human induced pluripotent stem cells (iPScs) have the potential to provide an 
unlimited source of hepatocytes for experimental analysis. We propose to generate ATD iPSc-
derived hepatocyte-like cells as a model for understanding the variability associated with ATD-
mediated liver disease. We believe that this would be a model that more faithfully recapitulates 
the human clinical condition and that can be used to validate the findings derived from other 
model systems. 
The goal of this study is to (1) generate iPScs from somatic cells of ATD patients 
with and without liver disease, (2) differentiate ATD iPScs into iPSc-derived hepatocyte-
like cells, and (3) determine the extent to which iHeps from ATD patients can model ATD. 
We hypothesize that iHeps from ATD patients can, not only model the primary genetic 
defect, but also the modifiers that define the patient-specific variations in severity of 
disease. 
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1.10.1 Reprogramming of alpha-1 antitrypsin deficient patient-derived somatic cells into 
iPScs 
We generated iPScs from primary hepatocytes or fibroblasts obtained from a normal control and 
ATD patients with varying degrees of liver disease using either viPS™ lentiviral gene transfer 
kit, non-integrating episomal plasmids, or a single excisable lentivirus cassette. The pluripotency 
of iPSc lines were confirmed by qPCR for the expression of pluripotency makers OCT3/4, 
NANOG, REX1 (ZFP42), TERT, TRA160 (PODXL), and DNMT3B, immunofluorescent staining 
for the pluripotency markers OCT3/4, NANOG, SOX2, TRA160, and SSEA4, teratoma 
formation assay in NOD/SCID mice. Finally, genomic DNA sequencing was performed to 
confirm the genotype of the generated iPSc lines. 
 
1.10.2 Differentiation of alpha-1 antitrypsin deficient patient-derived iPScs into 
hepatocyte-like cells 
We differentiated ATD and wild type iPScs into iHeps using a variation of the 4-step protocol 
described by Si-Tayeb116. At the end of each step of the differentiation, changes in mRNA 
expression of stage specific markers (NANOG, OCT3/4, CXCR4, FOXA2, and HNF4A) were 
monitored by qPCR to ensure hepatocyte-directed differentiation. At the end of the 
differentiation, immunofluorescent staining was done to determine the percentage of iHeps 
expressing mature hepatocyte markers (ALB and ASGPR1) and those expressing immature 
hepatocyte markers (ALB and AFP). The iHeps were further characterized by examining their 
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ultrastrucure using transmission electron microscopy (TEM). Finally, the ability of iHeps to 
functionally secrete ALB and AT was assayed by ELISA. 
 
1.10.3 Modeling the pathogenesis and variability of alpha-1 antitrypsin deficiency using 
patient-derived iPSc generated hepatocyte-like cells 
We first tested the ability of ATD iHeps to model the known biochemical abnormalities 
associated with the misfolded ATZ molecule. The kinetics of ATZ processing and secretion in 
ATD iHeps was assayed using pulse-chase radiolabeling and PNGase F/Endo H deglycosylation 
assays. We then examined the extent to which ATD iHeps can model the morphological and 
ultrastructural characteristics of the disease using immunofluorescense staining for AT and 
rER/Golgi markers and TEM. Finally, we determined whether there are differences in the 
kinetics of intracellular ATZ degradation and ultrastructural features of severe LD and no LD 
iHeps using pulse-chase labeling and TEM. 
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2.0  REPROGRAMMING OF ALPHA-1 ANTITRYPSIN DEFICIENT PATIENT-
DERIVED SOMATIC CELLS INTO IPSCS 
2.1 INTRODUCTION 
Relatively little is known about why some people with the classical form of alpha-1 antitrypsin 
deficiency (ATD) develop life-threatening liver disease, necessitating liver transplantation, while 
others with the exact same genetic defect completely escape this clinical phenotype15. The 
inability to analyze patient-derived live human hepatocytes from ATD patients in any significant 
numbers presents a major obstacle in understanding the biology of ATD-mediated liver disease 
and for the development of novel drugs and therapies. While liver tissue from patients can be 
used for analyses, these samples can only reveal aspects of the disease at its culmination64, 153. 
Studies using cellular and animal models have provided invaluable insights into the pathobiology 
of the disease62, 64, 66, 68, 71, 72, 74, 154-156. However, except for patient-derived fibroblasts74, these 
model systems lack the genetic diversity of humans that seems to be at least partly responsible 
for the observed variation in liver disease phenotype74. While liver tissue from patients can be 
used for analyses, these samples can only reveal aspects of the disease at its culmination64, 153. 
Induced pluripotent stem cells (iPScs) generated from ATD patients have the potential to 
provide an unlimited source of hepatocytes for analysis97, 157-159. Here, we generated of multiple 
human iPSc lines using lentiviral, episomal plasmid constructs or excisable lentiviral stem cell 
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cassettes carrying reprogramming factors from primary human cells of a normal control and 
ATD patients with varying severity of liver disease following exposure to either. ATD iPScs can 
be used to produce theoretically unlimited numbers of ATD hepatocytes which can then be used 
to recapitulate pathologic tissue formation in vitro or in vivo, thereby providing a model which 
can represent the variability in liver disease phenotype. 
2.2 MATERIALS AND METHODS 
 
2.2.1 Use of human- and animal-derived tissues 
All human tissues were obtained with informed consent following guidelines approved by the 
Institutional Review Boards of the University of Pittsburgh, Boston University School of 
Medicine and Albert Einstein College of Medicine. All animal experiments were performed in 
accordance with the Institutional Animal Care and Use Committee of the University of 
Pittsburgh guidelines for human use of animals for research. 
 
2.2.2 Hepatocyte isolation from liver explants 
Primary hepatocytes from an ATD patient with severe liver disease were obtained from the 
explanted liver of an ATD patient who received a liver transplant. Hepatocytes were isolated by 
three-step collagenase perfusion as described previously160, 161. Briefly, silicone catheters were 
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inserted into the major portal and/or hepatic vessels and the tissue was perfused with Hank’s 
Balanced Salt Solution (HBSS) without calcium, magnesium or phenol red (Lonza Walkersville 
Inc., Walkersville, MD) to determine the vessel(s) that would provide the most uniform 
perfusion of the tissue. Purse string sutures were then tied around each vessel with its 
accompanying catheter to prevent the leakage of buffer around the catheter during the perfusion. 
Perfusion proceeded once all remaining major vessels on the cut surfaces were closed with 
sutures around catheters or with surgical grade super glue. The liver tissue was placed in a sterile 
plastic bag and connected to a peristaltic pump with flow rate between 35 to 240 ml/min. The 
bag containing the tissue was placed in a circulating water bath at 37°C and the tissue was 
perfused with HBSS supplemented with 0.5 mM ethylene glycol tetraacetic acid (EGTA) 
(Sigma-Aldrich Corp., St. Louis, MO) without recirculation. Chelation of calcium by EGTA aids 
in the dissolution of intercellular junctions between hepatocytes and in the washing of 
hematopoietic cells. A second, non-recirculating perfusion with HBSS without EGTA was 
performed to flush residual EGTA from the tissue since calcium is essential for collagenase 
enzyme activity. During the second perfusion step, CIzyme™ collagenase MA (VitaCyte, LLC, 
Indianapolis, IN) was reconstituted and sterile-filtered according to manufacturer’s 
recommendations. Just prior to the third perfusion step, 100 mg Clzyme™ collagenase MA and 
24 mg CIzyme™ BP Protease (VitaCyte, LLC, Indianapolis, IN) were mixed with 1L of Eagle's 
Minimum Essential Medium (EMEM) (Lonza Walkersville Inc., Walkersville, MD). The tissue 
was then perfused with this EMEM-collagenase solution with recirculation as long as needed to 
complete the digestion. The duration of perfusion with the EMEM-collagenase solution was 
determined by continuously monitoring tissue integrity. Perfusion was stopped when the liver 
tissue beneath the capsule surface was visibly digested and separated from the capsule. The 
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tissue was then transferred to a sterile plastic beaker that contained ice-cold EMEM and was 
gently cut with sterile scissors to release hepatocytes. The cell suspension was filtered through a 
sterile gauze-covered funnel to remove cellular debris and clumps of undigested tissue. 
Hepatocytes were enriched by three consecutive centrifugation steps each at 80xg for 6 min at 
4°C. After three washes in EMEM, hepatocytes were suspended in cold Hepatocyte Maintenance 
Medium™ (HMM) (Lonza Walkersville Inc., Walkersville, MD). Cell viability expressed as 
percentage of viable cells over the total cell number was assessed by trypan blue exclusion. For 
determining plating efficiency and for reprogramming, 1x106 cells were plated onto collagen-
coated 6-well plates and cultured for 2 hours in HMM™ with SingleQuots of 1x10-7M 
dexamethasone, 1x10-7M insulin, and 50 ug/mL gentamicin/amphotericin-B (Lonza Walkersville 
Inc., Walkersville, MD) and supplemented with 5% fetal bovine serum (FBS) (Atlanta 
Biologicals, Inc., Lawrenceville, GA) to facilitate cell attachment. The media was then switched 
to HMM™ with SingleQuots of 1x10-7M dexamethasone, 1x10-7 M insulin, and 50 ug/mL 
gentamicin/amphotericin-B (Lonza Walkersville Inc., Walkersville, MD) with no FBS and 
cultured overnight. Plating efficiency expressed as the percentage of cells that attached over the 
total number of plated cells was determined by counting the number of attached cells after 
detachment. Only cells with a viability of >80% and a plating efficiency of >70% were used for 
reprogramming. 
 
2.2.3 Cell culture 
Primary human fibroblasts were cultured in fibroblast medium containing Dulbecco's Modified 
Eagle Medium (DMEM) (Life Technologies, Carlsbad, CA) supplemented with 10% defined 
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fetal bovine serum (dFBS) (HyClone Laboratories, Logan, Utah), 1X L-glutamine (Life 
Technologies, Carlsbad, CA), 1X Minimum Essential Medium Non-Essential Amino Acids 
(MEM NEAA) (Life Technologies, Carlsbad, CA), and 1X penicillin-streptomycin (Life 
Technologies, Carlsbad, CA). Isolated primary human hepatocytes were cultured in HMM™ 
with SingleQuots of 1x10-7M dexamethasone, 1x10-7 M insulin, and 50 ug/mL 
gentamicin/amphotericin-B. 
iPScs and hEScs were grown on culture plates or dishes coated with hESc-qualified 
matrigel (BD Biosciences, San Jose, CA) and maintained in mTeSR1™ (STEMCELL 
Technologies Inc., Vancouver, BC, Canada) with media changes done everyday until the cells 
are ~80% confluent and ready for passage. iPScs were passaged according to standard feeder-
free protocol. Briefly, cells were washed with Dulbecco's Modified Eagle Medium/Nutrient 
Mixture F-12 (DMEM/F12) (Life Technologies, Carlsbad, CA) and incubated with 1 mL of 1 
mg/mL dispase (Life Technologies, Carlsbad, CA) at 37°C for 5-12 minutes until the colony 
edges start to detach. Cells were washed three times with DMEM/F12 and were given fresh 
mTeSR1™. Colonies were manually scratched using sterile 5 mL glass pipettes and were 
transferred into 15 mL conical tubes. Colonies were broken into smaller pieces by gentle 
aspiration using 5 mL glass pipettes. Detached colonies were centrifuged at 300 rpm for 5 
minutes at room temperature. Colonies were then resuspended in mTeSR1™ and transferred 
onto hESc-qualified matrigel-coated culture plates or dishes. The splitting ratio depends on the 
iPSc line and on the confluence prior to passaging but is generally 1:6 to allow a week before the 
next passage. 
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2.2.4 Generation of iPScs from somatic cells 
Reprogramming of hepatocytes and fibroblasts was done using three different techniques. For all 
reprogramming techniques, colonies that had similar morphology and growth characteristics to 
H1 hEScs were selected for expansion between 20-30 days after reprogramming. Colonies were 
visualized using an inverted microscope inside a laminar flow hood. Selected colonies were 
gently scratched off of the bottom of the culture plate using a glass aspirating pipette with a 
smooth end and manually transferred using a 20 uL pipette onto freshly-prepared hESc-qualified 
matrigel-coated 24-well plates. Colonies were allowed to attach for 2 days and incubated in 
mTeSR1™ with media changes done every 2 days. 
Lentiviral-mediated reprogramming was initiated using the viPS™ lentiviral gene 
transfer kit (Thermo Fisher Scientific, Waltham, MA) following the manufacturer’s instructions 
to ectopically express OCT3/4, NANOG, SOX2, LIN28, KLF4, and c-MYC. Primary fibroblasts 
or freshly-isolated hepatocytes were seeded onto 1 well of a hESc-qualified matrigel (BD 
Biosciences, San Jose, CA)-coated 6-well plate at 1x105 cells/well in either fibroblast media or 
HMM™ and allowed to attach overnight. The following day, after washing the cells with 
Dulbecco's Phosphate-Buffered Saline (DPBS) (Life Technologies, Carlsbad, CA), the cells were 
incubated in 1 mL of transduction media consisting of the cell type’s respective culture medium 
without serum and supplemented with 6 μg/ml polybrene (EMD Millipore, Billerica, MA) and 
each of the six lentiviruses (Thermo Fisher Scientific, Waltham, MA) at a multiplicity of 
infection (MOI) of 10. After 24 hours, the cells were washed 3X with DPBS and the cells were 
cultured in their respective media for 3 days. The culture medium was switched to mTeSR1™ 
starting on day 4 with media changes done every 2 days. Colonies started to appear within 15 
days with new colonies appearing until day 35. 
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Plasmid-mediated reprogramming was done according to a previously described 
protocol90 with some modifications. Primary fibroblasts were grown until the cells reach the log 
phase. Cells were trypsinized, washed twice with DPBS, and counted. For each nucleofection, 
1x106 cells were resuspended in 100 uL of the Amaxa™ normal human dermal fibroblast 
(NHDF) Nucleofector™ kit (Lonza Walkersville Inc., Walkersville, MD) containing 3 ug of 
each of the four expression plasmids encoding OCT3/4 and P53 shRNA, SOX2 and KLF4, l-
MYC and LIN28, and eGFP. Cells were nucleofected using program U-23 on an Amaxa™ 
Nucleofector™ II (Lonza Walkersville Inc., Walkersville, MD). Nucleofected fibroblasts were 
plated on hESc-qualified matrigel-coated plates, cultured in mTeSR1™ medium for a week 
under ambient oxygen conditions, and then transferred into reduced oxygen conditions (4% 
O2/5% CO2). Colonies started to appear within 20 days with new colonies appearing until day 
30. 
Reprogramming of fibroblasts using the excisable lentivirus cassette containing human 
OCT4, KLF4, SOX2, and c-MYC has been described162. Briefly, 1x105 human fibroblasts were 
seeded onto a gelatin-coated 35-mm plastic tissue culture dish and cultured in fibroblast medium. 
The next day polybrene (5 μg/ml) was added to the media, and the cells were infected with 
hSTEMCCA-loxP lentivirus at a multiplicity of infection of 10. The day after, the media was 
changed to serum-free iPSc media, and on day 6 the entire well was trypsinized and passaged at 
a 1:16 ratio by plating onto two 10-cm gelatin-coated culture dishes that were preseeded with 
mitomycin C-inactivated mouse embryonic fibroblasts (MEFs). iPSc colonies were mechanically 
isolated 30 days postinfection based on morphology and expanded on MEF feeders in iPSc 
media. The transfection of selected iPSc colonies for the excision of viral sequences was 
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performed using the HelaMONSTER® transfection reagent (Mirus Bio LLC, Madison, WI) 
according to manufacturer’s instructions. 
2.2.5 RNA Extraction, cDNA synthesis and qPCR 
Total RNA was isolated according to manufacturers’ instructions using the RNeasy Mini Kit 
(Qiagen, Germantown, MD). cDNA was synthesized according to manufacturers’ instructions 
using SuperScript III First-Strand Synthesis System and oligo dT primers (Life Technologies, 
Carlsbad, CA). qPCR was performed according to manufacturers’ instructions using the Taqman 
Fast Advanced Master Mix (Life Technologies, Carlsbad, CA) on a StepOnePlus Real-Time 
PCR System (Life Technologies, Carlsbad, CA) following the Fast Mode cycling conditions for 
Taqman Gene Expression Assays. H1 hESc cDNA was used as the positive cellular control. 
Primary hepatocyte cDNA was used as the negative cellular control. Nucelase-free water was 
used as the negative assay control. Coagulation factor VII (F7) was used as a non-pluripotent 
marker control. Values are shown as mean ± s.d. Taqman Gene Expression Assay IDs are listed 
in Table 2. 
Table 2. Taqman Gene Expression Assay IDs for the qPCR analysis for pluripotency factors 
Target Gene Gene Expression Assay ID Dye Quencher 
PPIA (Cyclophilin A) – Internal Control Hs99999904_m1 FAM NFQ 
OCT3/4 (POU5F1) Hs03005111_g1 FAM NFQ 
NANOG Hs02387400_g1 FAM NFQ 
REX1 (ZFP42) Hs01938187_s1 FAM NFQ 
TERT Hs00972656_m1 FAM NFQ 
TRA160 (PODXL) Hs01574644_m1 FAM NFQ 
DNMT3B Hs00171876_m1 FAM NFQ 
F7 Hs01551992_m1 FAM NFQ 
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2.2.6 Pluripotency-marker staining 
Antibodies and their corresponding dilutions are listed in Table 3. For nuclear staining, cells 
were washed with phosphate buffered saline (PBS) (Life Technologies, Carlsbad, CA) and fixed 
in 100% pre-chilled ethanol at -20°C overnight. After three PBS washes, cells were washed with 
wash buffer containing 0.1% bovine serum albumin (BSA) (Sigma-Aldrich Corp., St. Louis, 
MO), and 0.1% TWEEN 20® (Sigma-Aldrich Corp., St. Louis, MO) in PBS. Samples were then 
blocked and permeabilized in blocking buffer containing 10% normal donkey or goat serum 
(Santa Cruz Biotechnology, Dallas TX), 1% BSA, 0.1% TWEEN 20®, and 0.1% Triton X-100 
(Sigma-Aldrich Corp., St. Louis, MO) in PBS for 1 hour at room temperature. Cells were then 
stained with primary or conjugated antibodies in blocking buffer at 4°C overnight. After three 
washes with wash buffer, cells were stained with secondary antibodies for 1 hour in the dark at 
room temperature. After three washes with wash buffer, and three washes with PBS, cells were 
then incubated for 1 minute in 1 ug/mL Hoechst 33342 in PBS (Life Technologies, Carlsbad, 
CA), followed by three PBS washes before visualization. Cells were imaged on an IX71 inverted 
epifluorescent microscope (Olympus, Central Valley, PA). 
For membrane staining, cells were washed with PBS and fixed in 4% paraformaldehyde 
for 15 minutes at room temperature. After three cold PBS washes, cells were blocked in blocking 
buffer containing 3% BSA and 5% donkey serum in PBS for 2 hours at room temperature. Cells 
were then stained with conjugated antibodies in blocking buffer at 4°C overnight. After three 
washes with PBS, cells were then incubated for 1 minute in 1 ug/mL Hoechst 33342 in PBS, 
followed by three PBS washes before visualization. Cells were imaged on an IX71 inverted 
epifluorescent microscope. 
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Alkaline phosphatase staining of cells was performed using the Vector® Blue Alkaline 
Phosphatase Substrate (Vector Laboratories, Inc., Burlingame, CA) according to manufacturer’s 
recommendations. Cells were imaged on an IX71 inverted epifluorescent microscope using light 
microscopy settings. 
Table 3. List of antibodies and dilutions used for the immunofluorescent staining for pluripotency factors 
Antibody Manufacturer Host Catalogue No. Dilutions 
anti-NANOG Cell Signaling Technology, Beverly, MA mouse 4893S 1:2000 
anti-OCT3/4 Santa Cruz Biotech, Santa Cruz, CA rabbit sc-9081 1:250 
anti-SOX2 Millipore, Bedford, MA rabbit AB5603 1:300 
anti-SSEA4-Alexa Fluor 555 BD Biosciences, San Jose, CA mouse 560218 1:100 
anti-TRA-1-60-Alexa Fluor 488 BD Biosciences, San Jose, CA mouse 560173 1:100 
anti-rabbit IgG-Alexa Fluor 488 Life Technologies, Carlsbad, CA goat A11008 1:250 
anti-mouse IgG-Alexa Fluor 546 Life Technologies, Carlsbad, CA goat A11030 1:250 
2.2.7 Teratoma formation assay 
For each iPS cell line, a confluent well of cells was passaged according to standard protocols. 
Briefly, cells were washed with DMEM/F12 and treated with 1 mL of 1 mg/mL dispase for 5-12 
minutes at 37°C. Cells were washed three times with DMEM/F12 and were manually scratched 
using sterile 5 mL glass pipettes. Detached colonies were centrifuged at 300 rpm for 5 minutes at 
4°C. Colonies were then resuspended in chilled hESc-qualified matrigel and kept at 4°C. 
Colonies were subcutaneously injected into anesthetized nonobese diabetic/severe combined 
immunodeficiency (NOD/SCID) mice (Charles River, Malvern, PA). After 1-3 months, 
depending on tumor size, mice were anesthetized and sacrificed prior to tumor extraction. Fixed 
tissue samples were submitted to the Children’s Hospital of UPMC Histology Core Laboratory 
for embedding, sectioning and hematoxylin and eosin (H&E) staining. 
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2.2.8 Genomic DNA sequencing 
Genomic DNA was obtained using the DNeasy® Blood & Tissue kit (Qiagen, Germantown, 
MD). To ensure specificity, sequencing was performed using a nested PCR assay using 
AccuPrime™ Pfx DNA Polymerase (Life Technologies, Carlsbad, CA). First, 558bp of exon 5 
of the SERPINA1 containing the mutation site was amplified using amplifying primers (F: 
AAGATGGACAGAGGGGAGCC, R: CAGCACTGTTACCTGGAGCC). The amplicon was 
then sequenced using a sequencing primer (CAGCCAAAGCCTTGAGGAGG) that is 
downstream of the forward amplifying primer. Amplicons were submitted to the University of 
Pittsburgh Genomics and Proteomics Core Laboratories for sequencing. 
2.3 RESULTS 
iPSc lines were generated from 3 no liver disease (no LD) and 2 severe liver disease (severe LD) 
ATD PiZZ patients and a wild type control using lentiviral, plasmid-based, or excisable lentiviral 
stem cell cassette reprogramming (Table 4). Here, severe LD ATD iPScs are defined as cells 
generated from ATD patients less than 10 years of age who required liver transplantation and no 
LD ATD iPScs are defined as cells generated from ATD patients with lung disease but with no 
clinically overt symptoms of liver disease. 
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Table 4. Human induced pluripotent stem cell lines were generated from ATD patients with severe liver 
disease and those with lung disease but no liver disease, and wild type control 
Designation iPS cell line iPS cell source 
Reprogramming 
Method 
Pi 
Genotype 
Severe LD1 ATH1 
AT deficient human hepatocyte, 
Biopsy, Children’s Hospital of 
Pittsburgh of UPMC, 10-year old 
male that had a liver transplant 
Lentivirus ZZ 
Severe LD2 AAT2 
AT deficient dermal fibroblast, 
Biopsy, Einstein College of 
Medicine, 3 month old male with 
severe liver disease 
Non-integrating 
plasmids ZZ 
No LD1a AT10c15 AT deficient lung fibroblast, 
Biopsy, UPMC Presbyterian, 42 
year old female with COPD 
Lentivirus ZZ 
No LD1b AT10c16 
No LD2 100-3-Cr-1162 
AT deficient dermal fibroblast, 
Biopsy, Boston University School 
of Medicine, 64 year old female 
with COPD 
Single Excisable 
Lentiviral Stem 
Cell Cassette 
ZZ 
No LD3 103-3-Cr-1162 
AT deficient dermal fibroblast, 
Biopsy, Boston University School 
of Medicine, 47 year old female 
with COPD 
Single Excisable 
Lentiviral Stem 
Cell Cassette 
ZZ 
Wild type NFIF Normal dermal fibroblast Non-integrating plasmids MM 
iPScs were initially selected based on their morphologic resemblance to colonies of H1 
hEScs. All iPScs had high nuclear to cytoplasm ratio, well-defined cell membranes and distinct 
colony borders (Figure 1A). Colonies were then manually passaged several times to select for 
clones that could self-renew and maintain distinct colony borders (Figure 1B). The 
undifferentiated state of hEScs is characterized by alkaline phosphatase (AP) expression which 
indicates pluripotency and the potential for self-renewal163. Although the expression of AP alone 
does not necessarily reflect a fully reprogrammed state, it is a relatively uncomplicated method 
for selecting clones for more stringent analysis. iPSc clones that showed high alkaline 
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phosphatase activity were therefore selected for subsequent expansion and pluripotency testing 
(Figure 1C). 
 
 
Figure 1. Induced pluripotent stem cells (iPScs) were generated from ATD patients with severe liver disease 
(severe LD) and no overt liver disease (no LD) 
(A) Morphology of iPScs compared to H1 hEScs after initial colony selection. (B) Morphology of iPScs compared 
to H1 hEScs after several passages. (C) Alkaline phosphatase staining of wild type iPScs, severe LD iPScs and no 
LD iPScs compared to H1 hEScs. Low magnification (40X), High magnification (100X). 
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Reprogramming techniques that employ more than one vector (whether using viruses or 
plasmids) could result in the generation of reprogramming intermediates, cells expressing some 
but not all of the pluripotency factors required for full reprogramming81, 164. Reprogramming 
intermediates could also arise from cells in which the copy number for each of the pluripotency 
factors are not optimized. It is therefore important to perform stringent assays to test for the 
pluripotency of selected colonies. Standard qPCR assays for testing the pluripotency of hEScs 
include the measurement or detection of the expression of classical markers including OCT3/4, 
NANOG, SOX2, SSEA4, and TERT. However, a recent study that made use of live cell imaging 
analysis determined that truly reprogrammed colonies express the pluripotency-associated 
markers Tumor Rejection Antigen 160 (TRA160), DNA (Cytosine-5-)-Methyltransferase 3 Beta 
(DNMT3B) and Zinc Finger Protein 42 (ZFP42)164. The TRA160 antigen is a mucin-like antigen 
originally discovered on human embryonic carcinoma (EC) progenitor cells but has since been 
shown to be detected on the membrane of several other stem cells. The molecular identity of the 
TRA160 antigen was unknown until 2007 when a study determined that it is present on the 
glycosylated cell adhesion protein Podocalyxin (PODXL) in EC cells165. DNMT3B is a DNA 
methyltransferase that is essential for epigenetic control early in human development. It 
functions for de novo methylation (as opposed to maintenance methylation) and is therefore 
essential for setting up DNA methylation patterns during genomic imprinting and X-
chromosome inactivation166. ZFP42, originally known as Reduced Expression 1 (REX1), is a 
zinc finger family transcription factor that is highly expressed in hEScs and is plays an important 
role in the maintenance of pluripotency as well as in the reprogramming of somatic cells to 
iPScs167, 168. We therefore analyzed the expression of all of these markers to confirm the 
pluripotency of the iPSc lines. 
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qPCR analysis revealed that the all iPSc lines expressed OCT3/4, NANOG, REX1 
(ZFP42), and TERT at levels that were similar to those in the H1 hEScs (Figure 2A). 
Surprisingly, the expression of DNMT3B and TRA160 (PODXL) and was highly elevated in all 
iPSc lines by at least two-fold compared to H1 hESc (Figure 2A). A recent study determined that 
among the more than 40 DNMT3B mRNA splice variants, only the alternatively spliced mRNA 
transcripts that contain exon 10 are true markers of pluripotency166. This new information 
prompted us to go back and check whether the qPCR primers we used for DNMT3B is specific 
for pluripotent-specific variants. Because the primers we used are specific for exons 6 to 8, the 
gene expression we obtained in our qPCR analysis is likely an overestimate of the actual level of 
pluripotent-specific DNMT3B mRNA. On the other hand, the highly glycosylated PODXL 
glycoprotein can be expressed in distinct forms in different cell types, a larger form that is 
modified with keratan sulfate glycosaminoglycan moieties, and a smaller form that is heavily 
glycosylated but contains no glycosaminoglycan groups. Only the larger form carries the 
pluripotency-defining TRA160 epitope165. Because the difference between the large and small 
form of PODXL is a result of post-translational modification, it is impossible to determine the 
level of pluripotent-specific PODXL by qPCR. We therefore confirmed the pluripotency of our 
iPSc lines by immunofluorescence analysis. Immunofluorescent staining for NANOG, OCT3/4, 
SOX2, SSEA4 and TRA160 in all iPSc lines revealed comparable expression to H1 hEScs thus 
confirming the pluripotency of the iPScs (Figure 2B). Careful inspection of immunofluorescence 
images reveals that each cell in a hESc or iPSc colony has a variable level of pluripotency 
marker expression. However, this heterogeneity in the expression of pluripotency markers 
appears to be a normal occurrence as has been reported in both hEScs and iPScs using 
fluorescence activated cell sorting (FACS) analysis168 or single cell transcriptional profiling169. 
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Figure 2. Induced pluripotent stem cells (iPScs) expressed pluripotency-associated markers 
(A) qPCR for pluripotency-associated markers OCT3/4, NANOG, REX1 (ZFP42), TERT, TRA160 (PODXL), and 
DNMT3B in H1 hEScs and iPScs. Coagulation Factor VII (F7) was used as a non-pluripotent marker control while 
primary hepatocyte was used as a negative cellular control. (B) Immunofluorescent staining for pluripotency-
associated markers NANOG, OCT3/4, SOX2, SSEA4 and TRA160 in H1 hEScs and iPScs (200X). 
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Although determining the expression of pluripotency-associated markers is a quick 
method for assessing pluripotency, the analysis of their ability to generate teratomas when 
injected subcutaneously into immunodeficient NOD/SCID mice is regarded as the gold standard 
for demonstrating the pluripotency of human iPScs170, 171. Two to three months after 
transplantation, all iPSc lines produced mature, cystic masses (Figure 3A). Upon histological 
analysis, the teratomas were shown to contain tissues derived from the embryonic germ layers 
endoderm, mesoderm and ectoderm, confirming the pluripotency of the iPSc lines (Figure 3B). 
 
 
Figure 3. Induced pluripotent stem cells (iPScs) generate teratomas when injected in immunodeficient NOD 
SCID mice 
(A) Teratomas formed by wild type, severe LD and no LD iPScs. (B) Selected slides showing areas of endodermal 
(gut-like epithelium), mesodermal (cartilage), and ectodermal (neural tissue) derivatives observed in severe LD1 
iPSc-generated teratoma (200X). 
 
Finally, to ensure that the generated iPScs carried the Pi genotype of the parental cell 
lines, we performed genomic DNA sequencing. DNA sequencing confirmed that the wild type 
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iPScs have the PiMM genotype (G11940, Glu342) while the ATD iPScs carried the PiZZ 
genotype (G11940A, Glu342Lys) (Figure 4). 
 
 
Figure 4. ATD iPScs carry homozygous G11940→A PiZ alleles while wild type iPScs were homozygous for 
the WT alleles 
Genomic DNA sequencing of exon 10 of the protease inhibitor gene 1 (SERPINA1) in wild type, severe LD and no 
LD iPScs. Wild type iPScs have the PIMM genotype (G11940, Glu342) while severe LD and no LD iPScs carry the 
PiZZ genotype (G11940A, Glu342Lys). 
2.4 DISCUSSION 
The generation of iPScs from ATD patients has been reported in numerous studies97, 157-159. 
However, to our knowledge, there have been no studies that generated iPScs from ATD patients 
representing the observed variability in liver disease phenotypes. Here, we generated iPScs from 
primary hepatocytes or fibroblasts of ATD patients with varying degrees of liver disease using 
either viPS™ lentiviral gene transfer kit, non-integrating episomal plasmids, or a single excisable 
lentivirus cassette. At the beginning of the study, only retroviral- and lentiviral-mediated 
reprogramming methods were available for the generation of iPScs81, 82. We decided to use 
lentiviruses for the initial reprogramming experiments because of two reasons. First, direct 
infection of human cells with retroviruses only results in 20% transduction81. Retroviral-
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mediated reprogramming therefore required an extra initial lentiviral transduction step that 
introduced the mouse receptor for retroviruses (Slc7a1) to increase retroviral delivery of 
reprogramming factors to 60%81. Second, retroviruses are very inefficient at infecting slow-
dividing or non-dividing cells such primary hepatocytes. Using lentiviral transduction, we 
successfully generated iPScs from primary hepatocytes and fibroblasts at reprogramming 
efficiencies of 0.001-0.008%. In the years following the initial stages of the study, several groups 
developed new reprogramming techniques that generate iPScs at higher efficiencies and with no 
integration of exogenous genetic sequences90, 162. We, and our collaborators therefore generated 
iPScs using either non-integrating episomal plasmids90, or single excisable lentivirus cassette162. 
Using these techniques, reprogramming efficiencies were increased by more than ten-fold (0.03-
0.1%). Despite the use of different cell sources and reprogramming method for generating iPScs, 
minimal differences were detected when iPScs were subjected to stringent pluripotency assays. 
The cell lines have similar morphology and growth properties compared to H1 hEScs, expressed 
the pluripotency-associated markers NANOG, OCT3/4, SOX2, SSEA4, TRA160, TERT, 
DNMT3B, and REX1 and were able to generate tumors when injected into immunodeficient 
mice. 
In our attempts to generate iPScs using the various available reprogramming protocols, 
we occasionally observed that some primary cells, particularly those that were derived from 
older patients or fibroblasts that were passaged multiple times, could not generate iPScs even 
after several attempts. One common characteristic of these reprogramming-resistant cells is that 
they have very low proliferation rates in vitro. We therefore speculate that the inability of such 
cells to generate iPScs is due to cellular senescence. Cellular senescence, characterized by an 
irreversible arrest in cell proliferation, has been strongly associated to physiological aging. 
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Studies have shown that several forms of cellular stress, including the activation of oncogenes, 
telomere shortening, DNA damage, oxidative stress, and mitochondrial dysfunction induce 
senescence. Because reprogramming is a stochastic process that is partially dependent on 
accelerated cell proliferation rate172, it is logical to think that slow-dividing cells would have a 
drastically lower probability to be reprogrammed to pluripotency. 
Because the ATD iPScs were generated from patients that represent the spectrum of 
disease severity, the cells can be used to produce various cell types which can then be used to 
study variability in ATD-mediated liver or lung pathologies. In the context of liver disease, the 
ATD iPScs could be used to generate hepatocytes for analyzing genetic differences between 
hepatocytes from patients with liver disease and those without liver disease that could explain 
why only a subset of PiZZ individuals develop significant liver injury. Likewise, the ATD iPScs 
could also be used to analyze genetic differences between lung epithelial cells, lung fibroblasts 
or macrophages that could explain variability in the severity of lung disease. 
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3.0  DIFFERENTIATION OF ALPHA-1 ANTITRYPSIN DEFICIENT PATIENT-
DERIVED IPSCS INTO HEPATOCYTE-LIKE CELLS 
3.1 INTRODUCTION 
Although the retention of mutant alpha-1 antitrypsin Z protein (ATZ) within hepatocytes is a key 
step in the pathogenesis of alpha-1 antitrypsin deficiency (ATD), it does not explain why only a 
small subset of PiZZ individuals develops significant liver injury15. The ability to study patient-
derived live human hepatocytes from ATD patients would be valuable in understanding the 
pathologic mechanisms of ATD because it could provide insights as to why variations in clinical 
phenotypes are observed between individuals sharing the same primary genetic mutation. 
However, because the disease is rare, primary hepatocytes from PiZZ patients are limited and are 
not readily available15. It is also difficult to recover hepatocytes from cirrhotic livers of ATD 
patients with severe liver disease. Moreover, long-term culture of primary hepatocytes has been 
difficult as hepatocytes lose their function and do not proliferate well in vitro125, 126. In addition, 
cryopreservation of hepatocytes results in reduced viability and metabolic function after 
thawing87, 127-136. 
Induced pluripotent stem cells (iPScs) could be used as an alternative source of hepatic 
cells to solve the paucity of liver cells for disease modeling. iPScs can proliferate indefinitely in 
vitro while maintaining the ability to differentiate into several different cell types81, 82, including 
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hepatocytes97, 116, 117. Because iPScs are patient-specific, they could be used to analyze patient-to-
patient variability in clinical phenotypes. In recent years, several groups have reported the 
generation of disease specific iPSc-derived hepatocyte-like cells (iHeps) for modeling several 
liver diseases using various hepatocyte differentiation approaches97, 98, 100, 157-159. 
One study described the generation of iHeps from three patients with ATD and showed 
the accumulation of AT polymers in ATD cells but not in control cells97. This demonstrates that 
iHeps from ATD patients can recapitulate some of the key pathological features of ATD in vitro. 
Moreover, the authors observed that the amount of ATZ polymers, while consistent among 
different iPSc lines from the same patient, varied between iPSc lines from different patients. 
Although not definitively analyzed in their study, the authors proposed that this variability in 
results between patient cells could correlate with severity of liver disease in patients. 
Here, we report the differentiation of iPScs from one wild type control and from five 
ATD patients into iHeps that exhibit many characteristics of primary human hepatocytes. 
Because the patient-specific ATD iHeps were derived from patients with or without severe liver 
disease, they could potentially be used to determine whether the biochemical and cellular 
characteristics of the iHeps correlate with liver disease severity in ATD patients. 
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3.2 MATERIALS AND METHODS 
 
3.2.1 Differentiation of ATD iPScs into hepatocyte-like cells 
Directed differentiation of iPS cells into iHeps was performed in vitro using a variation of the 4-
step protocol described by Si-Tayeb116. Briefly, iPS colonies were treated with accutase 
(STEMCELL Technologies Inc., Vancouver, BC, Canada) for 2-5 minutes to obtain single cells. 
mTESR1™ (STEMCELL Technologies Inc., Vancouver, BC, Canada) was added to the cells 
and centrifuged at 300 rpm for 5 minutes at room temperature. The cells were then transferred 
onto 6-well plates coated with growth factor reduced matrigel (BD Biosciences, San Jose, CA) at 
a density of 0.8-1x106 cells/well. Cells were allowed to attach by incubating at 4% O2/5% CO2 
for 20-22 hours. Cells were then induced to differentiate into definitive endoderm cells by 
treatment with Roswell Park Memorial Institute (RPMI) 1640 medium (Life Technologies, 
Carlsbad, CA), 1X B27 without insulin (Life Technologies, Carlsbad, CA) and 0.5X NEAA 
(Life Technologies, Carlsbad, CA) containing 100 ng/mL activin A (R&D Systems, 
Minneapolis, MN), 10 ng/mL recombinant human bone morphogenetic protein 4 (rhBMP4) 
(R&D Systems, Minneapolis, MN) and 20 ng/mL recombinant human fibroblast growth factor 2 
(rhFGF2) (BD Biosciences, San Jose, CA) for 2 days followed by treatment with RPMI 1640 
medium, 1X B27 without insulin and 0.5X NEAA with 100 ng/mL activin A for 3 days at 
ambient O2/5% CO2. For hepatic specification, the cells were cultured in RPMI 1640 medium, 
1X B27 with insulin (Life Technologies, Carlsbad, CA) and 0.5X NEAA containing 20 ng/mL 
rhBMP4 and 10 ng/mL rhFGF2 for 5 days at 4% O2/5% CO2. For hepatic induction, the cells 
were treated with RPMI 1640 medium, 1X B27 with insulin and 0.5X NEAA containing 20 
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ng/mL recombinant human hepatocyte growth factor (rhHGF) (R&D Systems, Minneapolis, 
MN) for 5 days at 4% O2/5% CO2. For hepatic maturation, the cells were cultured for 5 days in 
Hepatocyte Culture Medium™ Bullet Kit™ containing Hepatocyte Basal Medium™ with 
SingleQuots of ascorbic acid, fatty acid free bovine serum albumin, hydrocortisone, transferrin, 
insulin, gentamicin/amphotericin-B (minus epidermal growth factor) with 20 ng/mL recombinant 
human oncostatin M (rhOSM) (R&D Systems, Minneapolis, MN) at ambient O2/5% CO2. 
 
3.2.2 RNA Extraction, cDNA synthesis and qPCR 
Total RNA was isolated according to manufacturers’ instructions using the RNeasy Mini Kit 
(Qiagen, Germantown, MD). cDNA was synthesized according to manufacturers’ instructions 
using SuperScript III First-Strand Synthesis System and oligo dT primers (Life Technologies, 
Carlsbad, CA). qPCR was performed according to manufacturers’ instructions using the Taqman 
Fast Advanced Master Mix (Life Technologies, Carlsbad, CA) on a StepOnePlus Real-Time 
PCR System (Life Technologies, Carlsbad, CA) following the Fast Mode cycling conditions for 
Taqman Gene Expression Assays. Values are shown as mean ± s.d. Taqman Gene Expression 
Assay IDs are listed in Table 5. 
 
Table 5. Taqman Gene Expression Assay IDs for the qPCR analysis for pluripotency factors 
Target Gene Gene Expression Assay ID Dye Quencher 
PPIA (Cyclophilin A) – Internal Control Hs99999904_m1 FAM NFQ 
NANOG Hs02387400_g1 FAM NFQ 
OCT3/4 (POU5F1) Hs03005111_g1 FAM NFQ 
CXCR4 Hs00607978_s1 FAM NFQ 
FOXA2 (HNF3B) Hs00232764_m1 FAM NFQ 
HNF4A Hs00230853_m1 FAM NFQ 
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3.2.3 Immunofluorescent staining 
Antibodies and their corresponding dilutions are listed in Table 6. For cytoplasmic staining, cells 
were washed with phosphate buffered saline (PBS) (Life Technologies, Carlsbad, CA) and fixed 
in 4% paraformaldehyde for 15 minutes at room temperature. For nuclear staining, cells were 
washed with PBS and fixed in 100% pre-chilled ethanol at -20°C overnight. After three PBS 
washes, cells were washed with wash buffer containing 0.1% bovine serum albumin (BSA) 
(Sigma-Aldrich Corp., St. Louis, MO), and 0.1% TWEEN 20 (Sigma-Aldrich Corp., St. Louis, 
MO) in PBS. Samples were then blocked and permeabilized in blocking buffer containing 10% 
normal donkey or goat serum (Santa Cruz Biotechnology, Dallas TX), 1% BSA, 0.1% TWEEN 
20, and 0.1% Triton X-100 (Sigma-Aldrich Corp., St. Louis, MO) in PBS for 1 hour at room 
temperature. Cells were then stained with primary or conjugated antibodies in blocking buffer at 
4°C overnight. After three washes with wash buffer, cells were stained with secondary antibodies 
for 1 hour in the dark at room temperature. After three washes with wash buffer, and three 
washes with PBS, cells were then incubated for 1 minute in 1 ug/mL Hoechst 33342 (Life 
Technologies, Carlsbad, CA) in PBS, followed by three PBS washes before visualization. Cells 
were imaged on an IX71 inverted epifluorescent microscope (Olympus, Central Valley, PA). The 
percentage of cells that stained positive for the markers were determined using the Analyze 
Particle function of ImageJ software173. 
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Table 6. List of antibodies and dilutions used for the immunofluorescent staining for hepatocyte-directed 
differentiation 
Antibody Manufacturer Host Catalogue No. Dilutions 
anti-SOX17-Northern Lights 557 R&D Systems, Minneapolis, MN goat NL1924R 1:50 
anti-ALB Bethyl Laboratories, Montgomery, TX goat A80-229A 1:100 
anti-ASGR1 Santa Cruz Biotech, Santa Cruz, CA mouse sc-52623 1:100 
anti-AFP Life Technologies, Carlsbad, CA rabbit 18-0055 1:300 
anti-goat IgG-Alexa Fluor 488 Life Technologies, Carlsbad, CA donkey A11055 1:250 
anti-mouse IgG-Alexa Fluor 594 Life Technologies, Carlsbad, CA donkey A21203 1:250 
anti-rabbit IgG-Alexa Fluor 555 Life Technologies, Carlsbad, CA donkey A31572 1:250 
 
3.2.4 Sandwich ELISA 
Antibodies and their corresponding dilutions are listed in Table 7. For ALB, ELISA was done 
using the Human Albumin ELISA Quantitation Set (Bethyl Laboratories, Montgomery, TX) 
according to manufacturer’s protocol using Immulon™ 4HBX flat bottom microtiter plates 
(Thermo Fisher Scientific, Waltham, MA). The reaction was developed for 15 minutes with 100 
uL/well TMB substrate solution (KPL, Gaithersburg, MD) and stopped with 100 uL/well 0.18 M 
H2SO4. 
For AT, ELISA was carried out at room temperature and using 100 uL/well unless 
otherwise stated. Immulon™ 4HBX flat bottom microtiter plates were coated with coating 
antibody in 0.05M carbonate-bicarbonate buffer pH 9.6 for 1 hour. The wells were then washed 
five times with 200 uL ELISA wash solution (50 mM Tris, 0.14 M NaCl, 0.05% TWEEN 20, pH 
8.0) and blocked with 200 uL blocking buffer (50 mM Tris, 0.14 M NaCl, 1% BSA, pH 8.0) 
overnight at 4°C. Human AT standard (Athens Research and Technology, Athens, GA) and 
unknown samples were diluted in sample/antibody diluent (50 mM Tris, 0.14 M NaCl, 0.05% 
TWEEN 20, 1% BSA pH 8.0) and incubated for 1 hour. After washing five times, wells were 
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incubated with primary antibody diluted in sample/antibody diluent for 1 hour. After washing 
five times, wells were incubated with secondary antibody diluted in sample/antibody diluent for 
1 hour. The reaction was developed for 15 minutes with TMB substrate solution and stopped 
with 0.18 M H2SO4. 
HRP activity was measured in a Thermo-max microplate reader (Molecular Devices, 
Sunnyvale, CA) at 450 nm. Values are presented as mean ± s.d. with the significance calculated 
using one-way ANOVA followed by Bonferroni posttests for each pair of groups. 
 
Table 7. List of antibodies and dilutions used for sandwich ELISA 
Antibody Manufacturer Host Catalogue No. Dilutions 
anti-ALB (coating) Bethyl Laboratories, Montgomery, TX goat A80-129A 1:100 
anti-ALB-HRP (detection) Bethyl Laboratories, Montgomery, TX goat A80-129P 1:50000 
anti-AT (coating) Bethyl Laboratories, Montgomery, TX goat A80-122A 1:200 
anti-AT (primary) Dako, Carpinteria, CA rabbit A0012 1:80000 
anti-rabbit-HRP (detection) Dako, Carpinteria, CA goat P0448 1:5000 
 
3.2.5 Transmission Electron Microscopy 
iHeps were briefly washed with PBS, pH 7.4, fixed in situ with 2.5% glutaraldehyde in PBS for 
1 hour at room temperature and washed three times with PBS. Samples were submitted to the 
University of Pittsburgh Center for Biologic Imaging for post-fixation with 1% osmium tetroxide 
and 1% potassium ferricyanide for 1 hour at room temperature. Samples were washed three 
times with PBS and dehydrated in a graded series of ethanol solution (30%, 50%, 70%, and 90% 
- 10 minutes each) and three 15-minute changes in fresh 100% ethanol. Infiltration was done 
with three 1-hour changes of epon. The last change of epon was removed and beam capsules 
filled with resin were inverted over relevant areas of the monolayers. The resin was allowed to 
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polymerize overnight at 37°C and then for 48 hours at 60°C. Beam capsules and underlying cells 
were detached from the bottom of the petri dish and sectioned. Image acquisition was done using 
either the JEM-1011 or the JEM-1400Plus transmission electron microscopes (Jeol, Peabody, 
MA) at 80kV fitted with a side mount AMT 2k digital camera (Advanced Microscopy 
Techniques, Danvers, MA). 
3.3 RESULTS 
ATD and wild type iPScs were differentiated into iHeps in vitro following a variation of the 4-
step protocol described by Si-Tayeb116 (Figure 5A) because of a presumed need to obtain a 
homogenous population of cells with hepatocyte characteristics for further analysis. Changes in 
the morphology of the cells were observed as the cells progressed through the different stages of 
the differentiation protocol (Figure 5B). During the single cell passage step, cells were initially 
homogenously distributed throughout the plate but eventually migrate and come together to form 
small colonies or a network of cells (Figure 5B, first column). After the definitive endoderm 
step, about 50% of the cells die due to exposure to activin A, an outcome that has been reported 
in previous studies97, 116, 117. The surviving cells spread out and change morphology appearing 
larger and flatter compared to iPScs (Figure 5B, second column). In the hepatic specification 
step, the cells proliferate almost reaching confluency by the end of the stage. Small lipid droplets 
can be observed in the cytoplasm of some cells (Figure 5B, third column). In the hepatocyte 
induction stage, the cells proliferate slowly but begin to take the morphology of human 
hepatocytes, having a distinct polygonal shape with large cytoplasm and a well-defined plasma 
membrane (Figure 5B, fourth column). Most of the cells after this stage will exhibit lipid 
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droplets with some exhibiting double nuclei. In the hepatocyte maturation stage, the morphology 
of the cells does not change much compared to the previous stage. The cells continue to 
proliferate leading to overcrowding in some areas in the well (Figure 5B, last column). 
 
 
Figure 5. Changes in the morphology of iPScs during differentiation to iHeps 
(A) Schematic diagram outlining the protocol used to differentiate iPScs into iHeps from single cell passage, to 
definitive endoderm (DE) induction, hepatic specification, hepatocyte induction and hepatocyte maturation. The 
media composition for each stage is shown in black text while the culture conditions are shown in red text. (B) 
Morphology of wild type, severe LD1 and no LD1a iPScs as they progressed from being single iPS cells (100X) to 
definitive endoderm cells (100X), hepatoblasts (100X), immature hepatocytes (200X), and iHeps (200X). 
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To ensure hepatocyte-directed differentiation, changes in mRNA and protein expression 
of stage specific markers were monitored at the end of each step of the differentiation (Figure 6). 
The expression of the pluripotency factors OCT3/4 and NANOG was monitored in order to 
determine if any pluripotent cells exist after the differentiation. This was important because 
transplantation of differentiated cells could result in tumorigenesis if pluripotent cells are present 
in the transplanted cells. As expected, the expression of the pluripotency factors gradually 
decreased as the differentiation progressed (Figure 6A, upper panels). 
The expression of definitive endoderm markers Chemokine (C-X-C Motif) Receptor 4 
(CXCR4), Forkhead Box A2 (FOXA2) and Sex Determining Region Y box 17 (SOX17) was 
also monitored to determine the efficiency of definitive endoderm induction. The expression of 
CXCR4 was upregulated after the definitive endoderm stage and abruptly disappeared in the 
succeeding stages. FOXA2 expression was induced after the definitive endoderm stage and 
abruptly increased in the hepatic specification stage (Figure 6A, lower panels). This trend was 
expected since FOXA2 is not only essential for the formation of foregut DE cells, but is also 
necessary for further hepatic specification and liver bud differentiation during the development 
of the liver174, 175. However, FOXA2 expression unexpectedly declined towards the end of the 
differentiation. Immunofluorescent staining analysis showed that greater than 75% of cells after 
DE induction are SOX17-immunoreactive. This observed efficiency of DE induction is similar to 
what has been observed in other hepatocyte differentiation protocols of pluripotent stem cells116, 
117, 176. 
Hepatocyte Nuclear Factor 4 alpha (HNF4A) is essential for establishing the network of 
hepatic transcription factors that regulates hepatogenesis177. The expression of HNF4A was 
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therefore monitored as a marker for hepatocyte specification and maturation. After the hepatic 
specification stage, HNF4A was induced almost ten-fold to levels that were similar to that in 
primary human hepatocytes (Figure 6A, lower panels). However, HNF4A levels unexpectedly 
decreased towards the end of the differentiation (Figure 6A, lower panels). 
 
 
Figure 6. Differentiation of iPScs to iHeps results in changes in the expression of stage-specific markers 
(A) qPCR showing the downregulation of pluripotency-associated transcription factor NANOG and OCT3/4 
(POU5F1), expression of the definitive endoderm markers CXCR4 and FOXA2, and expression of the hepatocyte 
transcription factor HNF4A in iPS cells during the differentiation. Data shown as mean ± s.d. (n=3). DE: definitive 
endoderm, HS: hepatic specification, HI: hepatocyte induction, HM: hepatocyte maturation. (B) Immunofluorescent 
staining of iPS cells after the DE stage for the definitive endoderm marker SOX17 (100X). 
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At the end of the differentiation protocol, immunofluorescent staining was performed to 
determine the expression of hepatocyte markers ALB and ASGPR1, and the immature 
hepatocyte marker AFP. Quantification of stained images revealed that upon completion of 
hepatic maturation only 50-60% of iHeps expressed ALB (Figure 7). This efficiency of 
hepatocyte differentiation was lower than that observed for differentiation of iPScs reported 
previously116. About 30-40% of iHeps were positive for both ALB and ASGPR1 (Figure 7). 
However, 20-30% of the iHeps co-expressed ALB and AFP (Figure 7). This finding, together 
with the qPCR results showing the unexpected decrease in the expression of FOXA2 and HNF4A 
towards the end of the differentiation, suggests that the iHeps did not have a fully mature 
hepatocyte phenotype. 
 
 
Figure 7. ATD iHeps express mature hepatocyte markers ALB and ASGPR1 but have continued expression 
of the immature hepatocyte marker AFP 
Immunofluorescent staining of iHeps for mature hepatocyte markers ALB and ASGR1 and immature hepatocyte 
marker AFP (100X). 
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iHeps exhibited several ultrastructural features observed in primary human hepatocytes. 
The cells exhibited double nuclei, lipid droplets, glycogen rosettes and well-developed bile 
canaliculi with apical microvilli, desmosomes, and tight junctions as detected by transmission 
electron microscopy (Figure 8A). As a measure of function, the secretion of ALB and AT over a 
period of 24 hours was measured by ELISA (Figure 8B). iHeps were able to secrete ALB at 
levels that were ~40-50% of the amount secreted by primary human hepatocytes. Although the 
amount of ALB secreted by wild type and ATD iHeps were not significantly different, the levels 
of AT secreted by ATD iHeps were significantly lower compared to that secreted by wild type 
iHeps. This result was expected as the mutant ATZ molecule has a decreased ability to traverse 
the secretory pathway36 leading to reduced plasma AT levels in ATD patients4, 8, 19. 
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Figure 8. ATD iHeps exhibit many characteristics of primary human hepatocytes 
(A) Electron micrograph of iHeps showing double nuclei (n) and bile canaliculi (bc) with apical microvilli (mv), 
tight junctions (black arrowheads) and desmosomes (red arrowheads). (B) ELISA measuring the amount of ALB 
and AT secreted by the wild type iHeps (n=3), no LD iHeps (n=2), severe LD iHeps (n=4), and severe LD primary 
hepatocytes (n=2) over a period of 24 hours shown as mean ± s.d. ***p<0.001 (one-way ANOVA followed by 
Bonferroni posttests for each pair of samples). 
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3.4 DISCUSSSION 
In this study, we generated iHeps from ATD patients with and without severe liver disease with 
the ultimate goal of obtaining cells that could be analyzed to determine whether the biochemical 
and cellular features of the iHeps correlate with liver disease phenotype of ATD patients. The 
ATD and wild-type iHeps exhibited many of the characteristics of 1° human hepatocytes, but did 
not have a fully mature phenotype, as shown by the decrease in the expression of FOXA2 and 
HNF4A and the residual expression of the immature hepatocyte marker AFP. Nevertheless, the 
iHeps had endogenous production and secretion of AT, a cellular function that is essential for 
modeling the pathogenesis of ATD. 
We initially had concerns that the use of different cell sources and reprogramming 
methods for generating iPScs might lead to variability in the differentiation potential of the 
differentiated cells. However, we found that the degree of hepatocyte differentiation was 
equivalent across all iPSc lines irrespective of these factors based on the fact that the levels of 
secreted ALB as well as the percentage of ALB/ASGPR1 and ALB/AFP marker expression were 
similar across all iPSc lines. 
On some occasions, hepatocyte differentiation experiments failed to generate cells having 
the characteristics of primary hepatocytes. We found that in the majority of these failed 
differentiations, the percentage of SOX17+ cells was less than 75% after the definitive endoderm 
induction step. We therefore used SOX17 staining after the first step as a predictive tool to 
determine success of differentiation such that if we found less than 75% SOX17+ cells after the 
first step, the differentiation was discontinued. 
Based on our experience, there are several factors that are critical for the proper 
differentiation of iPScs into iHeps. It is essential to start with a well-maintained culture of iPScs 
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that have minimal spontaneously differentiated cells. Spontaneously differentiated cells in the 
starting culture respond differently to the growth factors in each stage of the differentiation and 
would generate cells that are a non-hepatocytic. In addition, these cells secrete their own growth 
factors that will alter the level and combination of growth factors in culture which can ultimately 
affect the differentiation of the cells surrounding it. The confluence and the tightness of the cells 
after single cell passage seems to have a huge impact on the differentiation specifically on the 
critical first step. It is important to start the first step of differentiation when the confluence is 
about 50-60% and when the cells have not yet formed tight colonies typically before 20 hours 
post passage (Figure 5B). We believe that this allows the growth factors to efficiently stimulate 
the cells. It is also important to ensure that the growth factors maintain their maximal biological 
activity. In order to avoid loss of bioactivity, growth factors should be frozen properly in their 
recommended buffers and should not be subjected to multiple freeze-thaw cycles. Lot-to-lot 
variability in the bioactivity of growth factors can also affect differentiation. Although time-
consuming, the best way to control for this is by performing side-by-side differentiations of the 
old and new batch of growth factor to determine comparable potency. 
Several hepatocyte differentiation protocols, including the protocol used in this study, 
have generated iHeps that display many features of primary mature hepatocytes97, 116, 117, 178. 
However, these iHeps have very high levels of AFP and exhibit underdeveloped mature 
hepatocyte function, such as inducible cytochrome P450 enzyme activity, indicating an immature 
phenotype. So far, only two protocols have been able to generate pluripotent stem cell-derived 
hepatocytes that exhibit mature hepatocyte function and that can engraft and expand after 
transplantation in rodent models of liver repopulation142, 179, 180. In these studies, differentiation 
occurred in the presence of other non-hepatic cells such as endothelial cells and mesenchymal 
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stem cells. We believe that the presence of these “supporting” cell types could significantly 
improve hepatocyte differentiation in vitro. 
 
 62 
4.0  MODELING THE PATHOGENESIS AND VARIABILITY OF ALPHA-1 
ANTITRYPSIN DEFICIENCY USING PATIENT-DERIVED IPSC GENERATED 
HEPATOCYTE-LIKE CELLS 
4.1 INTRODUCTION 
The classical form of alpha-1 antitrypsin deficiency (ATD), homozygous for the PiZ allele, is a 
single gene defect that is associated with liver disease and chronic obstructive pulmonary 
disease. The protein affected, alpha-1 antitrypsin (AT), is a secretory glycoprotein predominantly 
synthesized in hepatocytes and primarily functions to inhibit neutrophil elastase and several 
related neutrophil proteases. In individuals with ATD, the point mutation renders this protein 
prone to misfolding such that it accumulates in early compartments of the secretory pathway 
resulting in decreased levels of the protein in extracellular fluids1, 21, 33, 181. Lack of AT molecules 
to counteract neutrophil proteases is thought to be the primary mechanism for lung disease, a 
loss-of-function mechanism. In contrast, hepatic disease is caused by a gain-of-function 
mechanism attributable to the intracellular accumulation/“proteotoxicity” of mutant alpha-1 
antitrypsin Z (ATZ) in hepatocytes181. 
There is, however, a wide variability in incidence, severity and age of onset of ATD-
mediated liver disease15. While some affected homozygotes develop life-threatening liver 
disease, a considerable number never develop clinical symptoms and in some cases the liver 
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disease is first recognizable at 50-65 years of age. These observations have led us to theorize that 
genetic and/or environmental modifiers play a critical role in determining susceptibility to liver 
disease and that putative modifiers74 of pathways for intracellular ATZ degradation would be 
attractive targets for newly identified drug therapies66-68. 
Groundbreaking studies demonstrating that somatic cells can be reprogrammed into 
induced pluripotent stem cells (iPScs)81, 82, 88, 182 have created the opportunity to generate a 
variety of patient-specific somatic cell types including hepatocyte-like cells97, 116, 117, 142. Recent 
studies have demonstrated that iPSc-derived hepatocyte-like cells (iHeps) derived from patients 
with metabolic liver diseases, including ATD, could be utilized for disease modeling97, 98, 100, 157-
159. Here, we expand on previous work to investigate whether patient-specific iHeps could be 
used to model personalized variations in the severity of liver disease among ATD patients and 
ultimately be used to identify patients at risk for severe disease and address the “modifier” 
theory. 
4.2 MATERIALS AND METHODS 
 
4.2.1 Use of human-derived tissues 
All human liver tissues were obtained with informed consent following guidelines approved by 
the Institutional Review Board of the University of Pittsburgh. 
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4.2.2 Hepatocyte isolation from liver explants 
Primary hepatocytes from ATD patients with severe liver disease were obtained from the 
explanted liver of an ATD patient who received a liver transplant. Primary hepatocytes from 
normal controls were obtained from liver resection specimens containing normal tissues. 
Hepatocytes were isolated by three-step collagenase perfusion as described previously160, 161. 
Briefly, silicone catheters were inserted into the major portal and/or hepatic vessels and the 
tissue was perfused with Hank’s Balanced Salt Solution (HBSS) without calcium, magnesium or 
phenol red (Lonza Walkersville Inc., Walkersville, MD) to determine the vessel(s) that would 
provide the most uniform perfusion of the tissue. Purse string sutures were then tied around each 
vessel with its accompanying catheter to prevent the leakage of buffer around the catheter during 
the perfusion. Perfusion proceeded once all remaining major vessels on the cut surfaces were 
closed with sutures around catheters or with surgical grade super glue. The liver tissue was 
placed in a sterile plastic bag and connected to a peristaltic pump with flow rate between 35 to 
240 ml/min. The bag containing the tissue was placed in a circulating water bath at 37°C and the 
tissue was perfused with HBSS supplemented with 0.5 mM ethylene glycol tetraacetic acid 
(EGTA) (Sigma-Aldrich Corp., St. Louis, MO) without recirculation. Chelation of calcium by 
EGTA aids in the dissolution of intercellular junctions between hepatocytes and in the washing 
of hematopoietic cells. A second, non-recirculating perfusion with HBSS without EGTA was 
performed to flush residual EGTA from the tissue since calcium is essential for collagenase 
enzyme activity. During the second perfusion step, CIzyme™ collagenase MA (VitaCyte, LLC, 
Indianapolis, Indiana) was reconstituted and sterile-filtered according to manufacturer’s 
recommendations. Just prior to the third perfusion step, 100 mg Clzyme™ collagenase MA and 
24 mg CIzyme™ BP Protease (VitaCyte, LLC, Indianapolis, Indiana) were mixed with 1L of 
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Eagle's Minimum Essential Medium (EMEM) (Lonza Walkersville Inc., Walkersville, MD). The 
tissue was then perfused with this EMEM-collagenase solution with recirculation as long as 
needed to complete the digestion. The duration of perfusion with the EMEM-collagenase 
solution was determined by continuously monitoring tissue integrity. Perfusion was stopped 
when the liver tissue beneath the capsule surface was visibly digested and separated from the 
capsule. The tissue was then transferred to a sterile plastic beaker that contained ice-cold EMEM 
and was gently cut with sterile scissors to release hepatocytes. The cell suspension was filtered 
through a sterile gauze-covered funnel to remove cellular debris and clumps of undigested tissue. 
Hepatocytes were enriched by three consecutive centrifugation steps each at 80xg for 6 min at 
4°C. After three washes in EMEM, hepatocytes were suspended in cold Hepatocyte Maintenance 
Medium™ (HMM) (Lonza Walkersville Inc., Walkersville, MD). Cell viability expressed as 
percentage of viable cells over the total cell number was assessed by trypan blue exclusion. For 
determining plating efficiency and for reprogramming, 1x106 cells were plated onto collagen-
coated 6-well plates and cultured for 2 hours in HMM™ with SingleQuots of 1x10-7M 
dexamethasone, 1x10-7M insulin, and 50 ug/mL gentamicin/amphotericin-B (Lonza Walkersville 
Inc., Walkersville, MD) and supplemented with 5% fetal bovine serum (FBS) (Atlanta 
Biologicals, Inc., Lawrenceville, GA) to facilitate cell attachment. The media was then switched 
to HMM™ with SingleQuots of 1x10-7M dexamethasone, 1x10-7 M insulin, and 50 ug/mL 
gentamicin/amphotericin-B (Lonza Walkersville Inc., Walkersville, MD) with no FBS and 
cultured overnight. Plating efficiency expressed as the percentage of cells that attached over the 
total number of plated cells was determined by counting the number of attached cells after 
detachment. Only cells with a viability of >80% and a plating efficiency of >70% were used for 
kinetic analysis. 
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4.2.3 Pulse chase analysis and Densitometry  
Methods for biosynthetic labeling with 35S methionine, immunoprecipitation, sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), fluorography, and densitometric 
analysis have been described74. Briefly, cells were washed three times with Hank's Balanced Salt 
Solution (HBSS) (Life Technologies, Carlsbad, CA) and pulse-labeled with DMEM minus 
methionine and cysteine (Life Technologies, Carlsbad, CA) containing 250 uCi/mL TRAN35S-
LABEL™ metabolic labeling reagent (MP Biomedicals, Solon, OH) for 1 hour. Cells were then 
washed three times with HBSS and incubated in DMEM with methionine and cysteine (Life 
Technologies, Carlsbad, CA) without labeling reagent for several different time intervals to 
constitute the chase. The intracellular and extracellular fractions were subjected to 
immunoprecipitation with anti-AT nephelometric serum (Diasorin, Stillwater, MN) and the 
immunoprecipitates were analyzed by SDS-PAGE and fluorography. All fluorograms were 
subjected to densitometric analysis using ImageJ software173. The relative densitometric value at 
T0 is set at 100% and the remainder of the data set expressed as % of this value. Values are 
presented as mean ± s.d. with the significance calculated using two-way repeated measures 
ANOVA followed by Bonferroni posttests at each time point. Variations in rates of degradation 
and secretion within replicates and groups (wild type, severe LD, no LD) were within the range 
previously reported for pulse-chase analyses of this type21, 74. 
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4.2.4 Endoglycosidase H and PNGase F digestion  
Immunoprecipitates of pulse chase fractions were boiled in glycoprotein denaturing buffer 
containing 0.5% sodium dodecyl sulfate (SDS) and 0.04 M dithiothreitol (DTT) (New England 
Biolabs Inc., Ipswich, MA) for 10 mins. Samples were centrifuged at 13200 rpm for 10 mins. 
For endoglycosidase H (endo H), supernatants were added to a reaction containing 0.05 M 
sodium citrate pH 5.5 (G5 Reaction Buffer) (New England Biolabs Inc., Ipswich, MA), 1 mM 
phenylmethylsulfonyl fluoride (PMSF) (MP Biomedicals, Solon, OH), 10 uM pepstatin A (MP 
Biomedicals, Solon, OH), and 20 U/uL endo H (New England Biolabs Inc., Ipswich, MA) and 
incubated at 37°C for 1 hour. For PNGase F, supernatants were added to a reaction containing 
0.05 M sodium phosphate pH 7.5 (G5 Reaction Buffer) (New England Biolabs Inc., Ipswich, 
MA), 1% NP-40 (New England Biolabs Inc., Ipswich, MA), 1 mM PMSF (MP Biomedicals, 
Solon, OH), 10 uM pepstatin A (MP Biomedicals, Solon, OH), and 10 U/uL PNGase F (New 
England Biolabs Inc., Ipswich, MA) and incubated at 37°C for 1 hour. Samples were analyzed 
by analyzed by SDS-PAGE/fluorography. 
 
4.2.5 Immunofluorescent Staining 
Antibodies and their corresponding dilutions are listed in Table 8. Cells were washed with 
phosphate buffered saline (PBS) (Life Technologies, Carlsbad, CA) and fixed in 4% 
paraformaldehyde for 15 minutes at room temperature. After three PBS washes, cells were 
washed with wash buffer containing 0.1% bovine serum albumin (BSA) (Sigma-Aldrich Corp., 
St. Louis, MO), and 0.1% TWEEN 20 (Sigma-Aldrich Corp., St. Louis, MO) in PBS. Samples 
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were then blocked and permeabilized in blocking buffer containing 10% normal donkey or goat 
serum (Santa Cruz Biotechnology, Dallas TX), 1% BSA, 0.1% TWEEN 20, and 0.1% Triton X-
100 (Sigma-Aldrich Corp., St. Louis, MO) in PBS for 1 hour at room temperature. Cells were 
then stained with primary antibodies in blocking buffer at 4°C overnight. After three washes with 
wash buffer, cells were stained with secondary antibodies for 1 hour in the dark at room 
temperature. After three washes with wash buffer, and three washes with PBS, cells were then 
incubated for 1 minute in 1 ug/mL Hoechst 33342 (Life Technologies, Carlsbad, CA) in PBS, 
followed by three PBS washes before visualization. Cells were imaged on a Fluoview 1000 
confocal microscope (Olympus, Central Valley, PA). Confocal stacks were rendered using 
MetaMorph Image analysis software (Molecular Dynamics, Piscataway, NJ). Surface 
reconstructions were performed using Imaris Image analysis software (Bitplane USA, South 
Windsor, CT). 
 
Table 8. List of antibodies and dilutions used for colocalization of AT with rER and golgi markers 
Antibody Manufacturer Host Catalogue No. Dilutions 
anti-AT Bethyl Laboratories, Montgomery, TX goat A80-122A 1:1000 
anti-Calnexin Sigma-Aldrich Corp., St. Louis, MO rabbit HPA009433 1:100 
anti-Calreticulin Thermo Fisher Scientific, Waltham, MA rabbit PA3-900 1:1000 
anti-GM130 BD Biosciences, San Jose, CA mouse 610822 1:250 
anti-goat IgG-Alexa Fluor 488 Life Technologies, Carlsbad, CA donkey A11055 1:250 
anti-rabbit IgG-Alexa Fluor 555 Life Technologies, Carlsbad, CA donkey A31572 1:250 
anti-mouse IgG-Alexa Fluor 594 Life Technologies, Carlsbad, CA donkey A21203 1:250 
 
4.2.6 Transmission Electron Microscopy 
For iHeps, cell monolayers were briefly washed with PBS, pH 7.4. Samples were fixed in situ 
with 2.5% glutaraldehyde in PBS for 1 hour at room temperature and washed three times with 
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PBS.  Samples were submitted to the University of Pittsburgh Center for Biologic Imaging for 
post-fixation with 1% osmium tetroxide and 1% potassium ferricyanide for 1 hour at room 
temperature. Samples were washed three times with PBS and dehydrated in a graded series of 
ethanol solution (30%, 50%, 70%, and 90% - 10 minutes each) and three 15-minute changes in 
fresh 100% ethanol. Infiltration was done with three 1-hour changes of epon. The last change of 
epon was removed and beam capsules filled with resin were inverted over relevant areas of the 
monolayers. The resin was allowed to polymerize overnight at 37°C and then for 48 hours at 
60°C. Beam capsules and underlying cells were detached from the bottom of the petri dish and 
sectioned. For tissue samples, tissues were cut into 1mm3 blocks and fixed with 2.5% 
glutaraldehyde in PBS, pH 7.4 overnight and processed as for the cell cultures, except that tissue 
samples were further dehydrated in two 10-minute changes of propylene oxide. Samples were 
infiltrated with a 1:1 mix of propylene oxide and epon overnight and infiltrated with pure epon 
overnight at 4°C. Infiltration was continued with three 1-hour changes of epon. Samples were 
embedded in pure epon for 24 hours at 37°C and cured for 48 hours at 60°C. Image acquisition 
was done using either the JEM-1011 or the JEM-1400Plus transmission electron microscopes 
(Jeol, Peabody, MA) at 80 kV fitted with a side mount AMT 2k digital camera (Advanced 
Microscopy Techniques, Danvers, MA). Morphometric analysis of electron micrographs to 
determine the percentage of cells that contained globular inclusions was done by counting 
individual cells in the no LD1a iHeps (n=98), no LD2 iHeps (n=103), no LD3 iHeps (n=128), 
severe LD1 iHeps (n=97), and severe LD2 iHeps (n=111). Values are presented as mean ± s.d. 
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4.3 RESULTS 
 
4.3.1 iHeps from ATD patients recapitulate the accumulation and processing of the 
mutant ATZ molecule 
We used pulse-chase radiolabeling to analyze the kinetics of ATZ processing and secretion in 
iHeps from severe LD patients as the most sophisticated and definitive strategy to determine 
whether these cells model the known cellular defect that characterizes ATD. In both wild type 
iHeps and primary hepatocyte controls, AT is synthesized as a 52-kDa polypeptide that quickly 
becomes converted to a 55-kDa polypeptide. AT disappears from the intracellular compartment 
between 1 and 2 hours, coincident with appearance of the 55-kDa polypeptide in the extracellular 
medium (Figure 9A). In iHeps from severe LD patients, the 52-kDa ATZ polypeptide very 
slowly disappears from the intracellular compartment over the entire 4 hours of the chase period 
with minimal conversion to the 55-kDa polypeptide. A lesser amount of the 55-kDa ATZ 
polypeptide is detected in the extracellular fluid and it begins to appear only at the 3.0-hour time 
point (Figure 9A). The fate of ATZ in iHeps from severe LD patients was identical to its fate in 
primary hepatocytes from severe LD patients (Figure 9A). The half-time for the disappearance of 
AT from the intracellular compartment for wild type iHeps and primary hepatocyte controls was 
1.4 ± 0.1 hours as compared to 3.6 ± 0.4 hours for the iHeps and primary hepatocytes from 
severe LD patients (Figure 9B). 
 
 71 
 
Figure 9. ATD iHeps recapitulate the accumulation and secretion of ATZ observed in ATD primary human 
hepatocytes 
(A) Pulse-chase labeling showing intracellular accumulation of AT in severe LD cells but not in wild type cells. (B) 
Kinetics of the disappearance of AT in severe LD and wild type cells. Values are band densities of IC fractions in 
(A) relative to IC signal at time 0. 
 
Furthermore, analysis of the percentage of AT in the extracellular fluid at 3.0 and 4.0 
hours of the chase period relative to the amount of AT in the intracellular compartment at time 0 
revealed that iHeps and primary hepatocytes from severe LD patients have markedly reduced AT 
secretion compared to wild type iHeps and primary hepatocyte controls (Figure 10). This was an 
important analysis because we found that the relative rate of secretion of AT from wild type 
iHeps and primary hepatocyte controls is lower than in model cell lines generated by gene 
transfer. These cells include the HeLa HTO/M cell line (Figure 10), human fibroblast cell lines74, 
human hepatoma HepG2 and Hep3B cell lines, and human monocytes in primary culture21. This 
difference in rate of secretion of AT could therefore represent “leakiness” in the previous model 
cell lines or lack of full differentiated function in iHeps and primary hepatocytes in culture. 
Nevertheless, each of these cell systems are models and the important result is the clear 
difference in secretion between AT and the misfolded variant ATZ in each system. Thus, we 
conclude from the investigations thus far that iHeps from patients with severe LD accurately 
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model the intracellular accumulation and diminished secretion characteristic of the misfolded 
ATZ molecule21, 74. Indeed, this is the first time that this type of sophisticated kinetic analysis 
with pulse-chase radiolabeling has been used to definitively and quantitatively show that iHeps 
faithfully model the basic defect of the classical form of ATD and to provide quantitative rate 
measurements for the fate of ATZ. 
 
 
Figure 10. iHeps and primary hepatocytes secrete lower levels of AT in the extracellular fraction compared to 
HeLa inducible cell lines transduced to express wild type AT (HTO/M) or ATZ (HTO/Z) 
(A) Pulse-chase labeling comparing the AT in IC and EC fractions in the indicated cells. (B) Kinetics of the 
disappearance of AT in indicated cells. Values are band densities of IC fractions in (A) relative to IC signal at time 
0. (C) Band densities of the EC fractions in (A) at 3 hours (EC 3.0) and 4 hours (EC 4.0) relative to IC signal at time 
0. 
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Next we used the peptide-N-glycosidase F (PNGase F) deglycosylation assay to 
determine whether the AT and ATZ polypeptides undergoes N-linked glycosylation in the ER of 
iHeps. In both wild type and severe LD cells, the 52-kDa and 55-kDa AT polypeptides are 
PNGase-sensitive (Figure 11A) signifying that the AT and ATZ polypeptides received the N-
linked core glycan in the ER. We then performed the endoglycosidase H (endo H) 
deglycosylation assay to further characterize the fate of ATZ in the intracellular and extracellular 
compartment. In wild type iHeps and primary hepatocyte controls, the 52-kDa AT polypeptide is 
an endo H-sensitive partially glycosylated intermediate and the 55-kDa polypeptide that is 
detected intracellularly and extracellularly is endo H-resistant. In iHeps and primary hepatocytes 
from severe LD patients, the 52-kDa ATZ polypeptide that accumulates is endo H-sensitive 
whereas the very small amount of 55-kDa polypeptide that can be detected is endo H-resistant 
(Figure 11B). This indicates that the ATZ molecule that accumulates is a partially glycosylated 
intermediate and is predominantly localized to pre-Golgi compartments. This result is similar to 
what is observed in HeLa HTO/M and HTO/Z cell line models (Figure 11B). 
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Figure 11. The ATZ polypeptide accumulates as a partially glycosylated intermediate in iHeps and primary 
hepatocytes from patients with ATD 
Effect of PNGase F (A) and endo H (B) on AT in pulse-chase intracellular (IC) and extracellular (EC) fractions of 
indicated cells. (-) mock digestion, (+) enzyme digestion. 
 
4.3.2 iHeps from ATD patients with no liver disease more efficiently degrade misfolded 
ATZ 
Having established that ATD iHeps model the known biochemical abnormalities associated with 
the misfolded ATZ molecule72, 74, 183, we next investigated whether there is a difference in the 
fate of ATZ in severe LD and no LD iHeps using pulse-chase labeling (Figure 12A). In severe 
LD iHeps, intracellular ATZ slowly disappeared with more than ~30% of radioactively labeled 
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ATZ remaining after 4 hours. In no LD iHeps however, intracellular ATZ disappears more 
rapidly, beginning at the 2- and 3-hour time points with minimal radioactively labeled ATZ 
remaining at 4 hours (Figure 12, A and B). Intracellular ATZ disappeared slower in severe LD 
iHeps (p<0.005) with a half-time of 3.6 ± 0.1 hours compared to 2.2 ± 0.3 hours in no LD iHeps 
(Figure 12C). Quantitative accounting for all of the radiolabeled ATZ showed that the more 
rapid disappearance of ATZ from the intracellular compartment in the no LD iHeps could not be 
explained by increased secretion in the extracellular compartment (Figure 13) and is therefore 
entirely due to enhanced intracellular degradation. The validity of the modeling was apparent in 
several other ways. The kinetics of disappearance of ATZ was similar in iHeps from multiple 
iPSc clones from the same patient and in iHeps from unrelated PiZZ individuals that have the 
same liver disease phenotype (Figure 12, B and C). Thus, these results indicate that ATZ has a 
different fate in iHeps from ATD patients with liver disease with significantly slower 
intracellular degradation than in iHeps from ATD patients with no liver disease.  Importantly, the 
kinetic measurements of ATZ degradation in iHeps reported here are further validated by the fact 
that similar rates of ATZ degradation were observed years ago in genetically engineered skin 
fibroblasts from ATD patients74, a model system that lacked hepatocyte characteristics and 
proved unwieldy for long-term studies. The similarity in rates of degradation in these 2 different 
systems provides further evidence for the validity of the difference between severe LD and no 
LD patients and for the validity of the pulse-chase analytic method. 
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Figure 12. The rate of degradation of intracellular ATZ correlates with liver disease severity in ATD iHeps 
(A) Pulse-chase labeling comparing the disappearance of intracellular AT in severe and no LD iHeps. Severe LD1i 
and LD1ii are replicates from the same iPS cell line. No LD1a and no LD1b are different iPS cell clones from the 
same patient. (B) Kinetics of the degradation of AT in severe and no LD iHeps. Values are band densities of IC 
fractions in (A) relative to IC signal at time 0. (C) Composite curves of (B) shown as mean ± s.d. Dashed lines 
represent the half-time for disappearance of intracellular AT. **p<0.005 (two-way repeated measures ANOVA), 
++p<0.01, +++p<0.001, ++++p<0.0001 (Bonferroni posttests at each time point). Although densitometric values for 
the no LD iHeps appear to reach zero, the absolute values are <1% in B and C. 
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Figure 13. The disappearance of intracellular ATZ in no LD iHeps does not lead to increased secretion in the 
extracellular compartment 
Band density values of IC and EC fractions of wild type iHeps in Figure 9A and of severe LD and no LD iHeps in 
Figure 12A expressed as percentage of IC signal at time 0. 
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4.3.3 The mutant ATZ molecule accumulates in the rER as well as in non-rER 
compartments of ATD iHeps  
Having demonstrated that iHeps can model the fate of ATZ biochemically, we next examined the 
extent to which iHeps can model the disease morphologically. Early ultrastructural analysis of 
liver biopsies from ATD patients153, 184 as well as immunofluorescence studies of model cell 
lines transduced to express mutant ATZ185 have led to the belief that misfolded ATZ accumulates 
in the ER. To determine the sites of ATZ accumulation in severe LD iHeps, we performed 
double label immunofluorescence for AT and the rough ER (rER) markers calnexin and 
calreticulin. AT staining co-localized with rER markers but several large areas of AT 
accumulation did not (Figure 14, A to D). The fact that none of the large areas of ATZ 
accumulation co-localized with the Golgi marker GM130 (Figure 14, E and F), together with the 
Endo H studies (Figure 11) indicate that ATZ predominantly localizes to pre-Golgi 
compartments. The co-localization of ATZ and rER markers varied within and among cells 
(Figure 14G). Three-dimensional reconstruction of confocal image stacks from severe LD iHeps 
stained for AT and calnexin shows regions of ATZ accumulation that were enveloped by 
calnexin and others that were not. Some areas of calnexin-enclosed AT were also observed to be 
continuous with calnexin-free AT accumulation (Figure 14, H and I). These results suggest that 
ATZ accumulates not only in the rER but also in non-rER compartments. 
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Figure 14. ATZ in severe LD iHeps accumulates in rER and in compartments that are devoid of calnexin, 
calreticulin, or GM130 
Immunofluorescent staining of severe LD iHeps for AT and calnexin (A, B), calreticulin (C, D), or GM130 (E, F). 
A, C, E (600X), B, D, F (2000X). (G) Single stack image of severe LD iHeps stained for AT and calnexin. (H and I) 
3D surface reconstruction of multiple stacks of images of AT/calnexin-stained severe LD iHeps with calnexin signal 
made partially transparent to reveal AT staining inside calnexin staining. Nuclei are stained blue. 
 
Next we analyzed the ultrastructure of iHeps from severe LD patients and we used liver 
biopsy specimens from severe LD patients for comparison. In contrast to wild type iHeps which 
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displayed normal rER morphology, similar to those seen in wild type liver sections (Figure 15, A 
and B), severe LD iHeps had markedly dilated rER as well as abnormal globular inclusions, 
large vesicular structures enveloping proteinaceous material and partially covered with 
ribosomes (Figure 15, C and D). Liver sections from ATD patients with severe LD had similar 
morphological characteristics153 (Figure 15, E and F). The globular inclusions are filled with 
granular material that, in some areas, appears electron-dense. In some cells, the globular 
inclusions are almost completely devoid of ribosomes but because of the single plane of the 
image it is not possible to exclude the presence of some ribosome-containing areas. These 
observations are consistent with the double immunofluorescence and three-dimensional 
reconstructions (Figure 14, H and I) showing accumulation of ATZ in calnexin-positive and 
calnexin-free structures. These globular inclusions that are calnexin-free could represent 
dilations of smooth ER, specialized sub-domains of the rER or a completely separate 
subcompartment as has been observed for other misfolded proteins186.  While some cells in 
severe LD iHeps had normal looking organelles, many cells that contained inclusions had 
obvious accumulation of lipid droplets, autophagosomes, abnormal mitochondrial structures and 
fragmented Golgi (Figures 15C and 16 to 18), remarkably similar to what was seen in liver 
sections of ATD patients with severe LD153. Thus, using detailed immunofluorescent and 
ultramicroscopic analysis of iHeps from ATD patients, we provide evidence that iHeps 
recapitulate the morphological characteristics seen in the liver of ATD patients with severe LD 
and establish iHeps as an ideal model for analysis of the biology of the misfolded ATZ molecule 
at subcellular and biochemical levels, particularly because these cells are hepatocytic. 
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Figure 15. Severe LD iHeps and severe LD liver tissue sections exhibit dilated rER and dilated globular 
inclusions that are partially covered with ribosomes 
Electron micrograph of wild type iHeps (A), wild type liver tissue section (B), severe LD iHeps (C, D), and severe 
LD liver tissue section (E, F) showing normal rER (black arrows), dilated rER (blue arrows) and dilated globular 
inclusions that are partially covered with ribosomes (red arrows). m: mitochondria, ld: lipid droplets. 
 82 
 
Figure 16. Electron micrographs of severe LD iHeps (A-F) showing the presence of autophagosomes (black 
arrows) and autophagolysosomes (red arrows) 
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Figure 17. Mitochondrial dilation is evident in severe LD iHeps 
 (A and B) Electron micrograph of severe LD iHeps showing normal mitochondria (black arrows) and enlarged 
mitochondria (red arrows). (C and D) Immunofluorescent staining of severe LD iHeps for AT (red), TOM20 
(green), and nuclei (blue) showing dilated mitochondria in cells with increased AT accumulation (yellow arrows) 
compared to cells with minimal AT accumulation (white arrows) (1000X). 
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Figure 18. Golgi fragmentation is evident in severe LD iHeps 
 (A and B) Electron micrograph of severe LD iHeps showing normal Golgi (black arrows) and fragmented Golgi 
(red arrows). (C and D) Immunofluorescent staining of severe LD iHeps for AT (red), GM130 (green), and nuclei 
(blue) showing fragmented Golgi in cells with AT accumulation (yellow arrows) compared to cells with minimal 
AT accumulation (white arrows) (1000X). 
 
4.3.4 No LD iHeps lack intracellular inclusions that are the cellular hallmark of the 
disease 
Because liver biopsies are not routinely performed on ATD patients with no symptomatic liver 
disease, the ultrastructure of hepatocytes in this group of patients has not been studied. We 
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therefore used TEM to determine if there are ultrastructural differences between severe LD 
(Figure 19, A to C) and no LD iHeps (Figure 19, D to F). Although dilated rER was observed in 
iHeps from no LD patients, there was a remarkable absence of globular inclusions (Figure 19, D 
to F). Using quantitative morphometry, globular inclusions were observed in 26.59 ± 7% of 
iHeps from severe LD patients as compared to none of the iHeps from no LD patients. This 
suggests that the degradative response that leads to enhanced intracellular disposal of ATZ in no 
LD individuals, as shown by the pulse-chase results in Figure 12, A to C, might be sufficient to 
prevent this morphological hallmark of ATZ accumulation. Furthermore, this morphological 
difference could be used as a relatively straightforward diagnostic criterion to predict 
susceptibility to liver disease in individuals with ATD. 
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Figure 19. Severe LD iHeps and no LD iHeps exhibit dilated rER but only severe LD iHeps exhibit globular 
inclusions 
Electron micrograph of severe LD iHeps (A-C) and no LD iHeps (D-F) showing normal rER (black arrows), dilated 
rER (blue arrows) and globular inclusions that are partially covered with ribosomes (red arrows). ld: lipid droplets, 
n: nucleus, m: mitochondria. 
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4.4 DISCUSSSION 
Previous studies have described the use of patient-derived iHeps for modeling ATD97, 157-159. 
This study takes the technology one step further by demonstrating that patient-derived iHeps can 
model the biochemical and morphological manifestations of a primary genetic defect and the 
modifiers that correlate with the clinical phenotype in individual patients. 
From a cell biological perspective, the results provide support for the concept that quality 
control “proteostasis” mechanisms, in this case intracellular degradation pathway(s), play a 
critical role in determining the severity of disease, presumably by affecting the degree of 
“proteotoxicity”187. In terms of ATD, the current study supports a long-held hypothesis that 
variation in hepatic phenotype could be attributed at least in part to modifiers that target either 
intracellular degradation mechanisms or signaling pathways which facilitate adaptation of cells 
to accumulation of misfolded proteins74. Although the studies reported here do not identify the 
specific genes that represent the putative modifiers, we now know that the modifiers, at least in 
the patients investigated here, appear to be associated with the intracellular degradation pathways 
or regulators of those pathways. This finding is also important because it is possible, if not 
probable, that variation in the liver phenotype among ATD patients is due to genetic or 
environmental modifiers that lead to hepatocyte dysfunction completely independent of an effect 
on the fate of misfolded ATZ (e.g. steatosis, iron overload).  The results also indicate that iHeps 
will provide a valid system for identifying the mechanism by which putative modifiers affect the 
fate of ATZ. 
It was originally thought that misfolded ATZ accumulates only within the rER of 
hepatocytes153, 184, 185. However, results from our study also demonstrate the accumulation of 
ATZ in abnormal globular inclusions. These inclusions do not exhibit the normal characteristics 
 88 
of rER or Golgi because they are poorly studded with ribosomes and are devoid of classical rER 
and Golgi markers. While the identity of these globular inclusions has not been definitively 
established, our results showing that only iHeps from patients with severe liver disease contained 
inclusions suggests that the enhanced intracellular disposal of ATZ in ATD patients “protected” 
from liver disease is sufficient to prevent this morphological hallmark of ATZ accumulation. 
More importantly, this finding presents a major advance for clinical management of the disease 
as it may now be used to predict which individuals are susceptible to “proteotoxic” consequences 
and liver disease well before liver disease progresses to end-stage, necessitating liver 
transplantation. By showing that patients are susceptible to liver disease because their 
endogenous intracellular degradation mechanisms are not as efficient as in “protected” hosts, the 
results provide even more optimism for the recently identified therapeutic strategies utilizing 
drugs such as carbamazepine and fluphenazine, which enhance autophagic degradation of ATZ66-
68. 
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5.0  CONCLUSION 
The discovery that somatic cells can be reprogrammed into pluripotent stem cells, together with 
the development of more efficient in vitro differentiation techniques, has paved the way for a 
new source of human somatic cells for disease modeling. In recent years, a number of studies 
have shown that patient-derived iPScs can recapitulate the cellular manifestations of the primary 
genetic defect in various genetic diseases, including ATD93, 94, 96-98, 100, 111, 157-159, 188-192. However, 
for many genetic diseases, such as ATD-mediated liver disease, ATD-mediated lung disease, 
Alzheimer's disease, and hypertrophic cardiomyopathy, there is substantial clinical phenotypic 
variability such that patients carrying the same genetic mutation may present with severe, mild or 
no symptoms. The degree to which iPScs can also model the genetic modifiers that affect disease 
penetrance has not been investigated. 
In this study, we validate the usefulness of iPSc technology for disease modeling by 
demonstrating that patient-derived iHeps can model the pathogenesis and heterogeneity of ATD-
mediated liver disease. Although the studies reported here do not identify the specific genes that 
represent the putative modifiers, we have now confirmed that these modifiers are involved with 
the regulation of intracellular degradation pathways. The results also indicate that iHeps will 
provide a valid system for identifying specific modifier genes that could be potential 
pharmacological targets. Since iHeps can be generated from any and all ATD patients, it also 
allows for the development of personalized treatment strategies. Finally, iHeps could potentially 
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serve as a tool for assessing predisposition to liver dysfunction in ATD patients, either by pulse-
chase or by ultrastructural analysis. 
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6.0  FUTURE DIRECTIONS 
6.1 REPROGRAMMING OF ATD PATIENT-DERIVED SOMATIC CELLS USING 
SENDAI VIRUS 
Initial methods for generating iPScs from human somatic cells had low efficiencies and involve 
the insertion of exogenous genetic material into host cells. In recent years, there have been 
several studies that developed new methods for reprogramming that generate footprint-free iPScs 
at higher reprogramming efficiencies. Among these methods, the approach that has the greatest 
reprogramming efficiency uses the F-deficient Sendai viral vector (SeV). Using this method, 
neonatal and adult fibroblasts are reprogrammed to iPScs at efficiencies as high as 1%193. The 
Sendai virus has a genome in the form of a minus-sense single stranded RNA. Because it 
replicates in the cytoplasm of infected cells without the generation of DNA intermediates, it is 
impossible for the viral sequences to integrate into the host genome. Because entry of the virus is 
mediated by binding to sialic acid receptors present on the surface of many different cells, it is 
also a very efficient vector for introducing foreign genes in a wide spectrum of host cells. 
Although there are concerns that the SeV is difficult to remove from infected cells because they 
constitutively replicate, it has been reported that no residual virus is present by passage 10193. 
Moreover, a temperature-sensitive SeV has now been developed that allows complete loss of 
vector copy number in cytoplasm by increasing the temperature to 38-39°C194. This strategy 
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would therefore produce footprint-free iPScs that would be valuable for both disease modeling 
and cell transplantation. 
6.2 DIFFERENTIATION AND TRANSPLANTATION OF ATD PATIENT-DERIVED 
IPSCS TO GENERATE MATURE HEPATOCYTES 
Several protocols have described the differentiation of iPScs into iHeps that display many 
features of primary mature hepatocytes97, 116, 117, 178. However, some of the functions of these 
iHeps, such as inducible cytochrome P450 enzyme expression, are underdeveloped suggesting 
that these cells have a phenotype that is not fully mature. So far, only two protocols have been 
able to generate pluripotent stem cell-derived hepatocytes that exhibit mature hepatocyte 
function and that can engraft and expand after transplantation in rodent models of liver 
repopulation142, 179, 180. 
In one study, three-dimensional aggregates of pluripotent stem cells called embryoid 
bodies (EBs) are first generated and allowed to mature for 2 days142. This allows the 
differentiation of stem cells towards either endodermal, mesodermal, or ectodermal derivatives. 
EBs are then transferred in two-dimensional cultures and treated with growth factors that induce 
hepatogenesis in the endodermal cells. Some of the cells that differentiate towards other non-
hepatocytic lineages presumably become “supporting cells” that help the endoderm cells to 
differentiate into hepatocytes. Because there is a heterogeneous population of cells after the 
differentiation, mature hepatocytes are selected by florescence activated cell sorting for the 
mature hepatocyte marker ASGPR1. Transplantation of ASGPR1-expressing cells in rodent 
models for liver repopulation (Alb-uPA SCID mouse and retrorsine-treated/70% partially 
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hepatectomized immuosuppressed Nagase rat) showed that the cells were able to engraft in the 
host liver, expand in response to proliferation signals, and secrete liver-specific proteins. The 
rationale for this approach is that the non-hepatocyte cells presumably facilitate the 
differentiation and maturation of hepatocytes either by growth factor-mediated or contact-
mediated signaling. 
In another study, hepatocyte differentiation was performed in a three-dimensional culture 
system prior to tissue transplantation. When iPSc-derived hepatic endoderm, endothelial and 
mesenchymal cells are co-cultured, the cells spontaneously formed three-dimensional liver bud 
(LB) organoids capable of liver-specific functions such as protein production and human-specific 
drug metabolism179, 180. Transplantation of the LBs in the mesentery of a drug-induced mouse 
repopulation model (TK-NOG mouse) or the acute liver injury model (Alb-TRECK/SCID mice) 
also improved survival179. This study improved hepatocyte differentiation by using a three-
dimensional and multicellular approach to mimic liver development. 
Based on these studies, it appears that there is a significant improvement in hepatocyte 
differentiation in the presence of other cell types. EB-mediated and LB-mediated hepatocyte 
differentiations of ATD iPScs are promising methods for obtaining mature hepatocytes. 
Hepatocytes that are isolated and purified using ASGPR1-selection can then be used for in vitro 
analyses or can be transplanted into FRG mouse model for repopulation195 to generate an in vivo 
model for ATD. 
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6.3 ANALYSIS OF OTHER FORMS OF ATD-MEDIATED LIVER DISEASE 
In our studies, we used iHeps from ATD patients with severe liver disease during the childhood 
years. It will be interesting to determine if differences in kinetic characteristics or morphology 
can be ascertained in iHeps representing the other forms of ATD liver disease, with onset in 
adolescence or adult years, or with isolated hepatocellular carcinoma. It will also be important to 
determine if the kinetic and morphological characteristics are stable when collected from single 
individuals serially over time. We suspect that these characteristics will be stable over time 
because of the similarities in mean rate of intracellular degradation for each group when 
investigated in the previously reported fibroblast cell lines74 and iHeps in this report and because 
the iHeps from ATD patients with no liver disease, which had a relatively increased rate of 
intracellular degradation, were established from these patients at adult ages of 42-67 years. If not 
stable we would have expected this rate of degradation to decrease with age. 
6.4 INDENTIFICATION OF MODIFIER GENES FOR ATD 
Results from this study demonstrate the ability of patient-derived iHeps to model the 
heterogeneity of ATD-mediated liver disease. Although this study does not identify the specific 
genes that represent the modifiers of disease susceptibility, it provides a reliable system for 
identifying and validating specific modifier genes. Recent studies using genome-wide RNAi 
screens and genetic crosses in a C. elegans model for ATD have identified genetic modifiers 
affecting the accumulation of the alpha-1 antitrypsin Z mutant (ATZ)69, 70. An important next 
step would be to employ gene-targeted approaches to confirm the involvement of these putative 
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modifier genes on the phenotype (ultrastructural characteristics and kinetics of ATZ disposal) of 
ATD iHeps. Genetic knockdown of modifier genes (or their endogenous inhibitors) can be done 
using siRNA or shRNA technology. Genomic editing using either Zinc Finger Nucleases 
(ZFN)103 and piggyBac technology104, 105, Clustered Regularly Interspaced Short Palindromic 
Repeat (CRISPR)/CRISPR-associated nuclease 9 (CRISPR/Cas9) system106 or Transcription 
Activator-Like Effector Nucleases (TALENs)107 can also be used to introduce specific mutations 
in modifier genes that would render the gene product inactive. Genomic editing could also be 
done to correct variants of modifier genes that increase susceptibility to liver disease and 
determine the effects on overall phenotype. 
6.5 DRUG TREATMENT OF ATD IHEPS 
From this study, we know that the modifiers, at least in the iHeps we studied, are involved with 
the regulation of intracellular degradation pathways. Moreover, results of genome-wide RNAi 
screens, genetic crosses, and pharmacological screens in a C. elegans model for ATD identified 
autophagy and ER-associated degradation (ERAD) pathways as critical for the degradation of 
intracellular ATZ67-70. The next step would be to determine if the treatment of severe LD iHeps 
with drugs that activate specific components of the autophagic degradation or ERAD pathways 
would result in decrease of intracellular ATZ load and the loss of globular inclusions. 
Conversely, it would also be valuable to determine whether the treatment of no LD iHeps with 
inhibitors of autophagic or preoteosomal degradation pathways would increase ATZ load and 
allow the emergence of globular inclusions. 
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